

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 413/00, A61K 31/44		A1	(11) International Publication Number: WO 97/36898
			(43) International Publication Date: 9 October 1997 (09.10.97)
(21) International Application Number: PCT/US97/05512		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 1 April 1997 (01.04.97)		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(30) Priority Data: 60/014,592 3 April 1996 (03.04.96) US 9613462.2 27 June 1996 (27.06.96) GB 60/022,342 24 July 1996 (24.07.96) US 9617280.4 16 August 1996 (16.08.96) GB			
(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			
(72) Inventor; and (75) Inventor/Applicant (for US only): ANTHONY, Neville, J. [GB/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			
(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			
(54) Title: INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE			
(57) Abstract <p>The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

TITLE OF THE INVENTION

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

BACKGROUND OF THE INVENTION

5 The Ras proteins (Ha-Ras, Ki4a-Ras, Ki4b-Ras and N-Ras) are part of a signalling pathway that links cell surface growth factor receptors to nuclear signals initiating cellular proliferation. Biological and biochemical studies of Ras action indicate that Ras functions like a G-regulatory protein. In the inactive state, Ras is bound to GDP.

10 Upon growth factor receptor activation Ras is induced to exchange GDP for GTP and undergoes a conformational change. The GTP-bound form of Ras propagates the growth stimulatory signal until the signal is terminated by the intrinsic GTPase activity of Ras, which returns the protein to its inactive GDP bound form (D.R. Lowy and

15 D.M. Willumsen, *Ann. Rev. Biochem.* 62:851-891 (1993)). Mutated *ras* genes (Ha-*ras*, Ki4a-*ras*, Ki4b-*ras* and N-*ras*) are found in many human cancers, including colorectal carcinoma, exocrine pancreatic carcinoma, and myeloid leukemias. The protein products of these genes are defective in their GTPase activity and constitutively transmit

20 a growth stimulatory signal.

Ras must be localized to the plasma membrane for both normal and oncogenic functions. At least 3 post-translational modifications are involved with Ras membrane localization, and all 3 modifications occur at the C-terminus of Ras. The Ras C-terminus

25 contains a sequence motif termed a "CAAX" or "Cys-Aaa¹-Aaa²-Xaa" box (Cys is cysteine, Aaa is an aliphatic amino acid, the Xaa is any amino acid) (Willumsen *et al.*, *Nature* 310:583-586 (1984)). Depending on the specific sequence, this motif serves as a signal sequence for the enzymes farnesyl-protein transferase or geranylgeranyl-protein

30 transferase, which catalyze the alkylation of the cysteine residue of the CAAX motif with a C₁₅ or C₂₀ isoprenoid, respectively. (S. Clarke., *Ann. Rev. Biochem.* 61:355-386 (1992); W.R. Schafer and J. Rine, *Ann. Rev. Genetics* 30:209-237 (1992)). The Ras protein is one of several proteins that are known to undergo post-translational farnesyl-

- 2 -

ation. Other farnesylated proteins include the Ras-related GTP-binding proteins such as Rho, fungal mating factors, the nuclear lamins, and the gamma subunit of transducin. James, et al., *J. Biol. Chem.* 269, 14182 (1994) have identified a peroxisome associated protein Pxf which is also
5 farnesylated. James, et al., have also suggested that there are farnesylated proteins of unknown structure and function in addition to those listed above.

Inhibition of farnesyl-protein transferase has been shown to block the growth of Ras-transformed cells in soft agar and
10 to modify other aspects of their transformed phenotype. It has also been demonstrated that certain inhibitors of farnesyl-protein transferase selectively block the processing of the Ras oncoprotein intracellularly (N.E. Kohl *et al.*, *Science*, 260:1934-1937 (1993) and G.L. James *et al.*, *Science*, 260:1937-1942 (1993). Recently, it has been shown that an
15 inhibitor of farnesyl-protein transferase blocks the growth of *ras*-dependent tumors in nude mice (N.E. Kohl *et al.*, *Proc. Natl. Acad. Sci U.S.A.*, 91:9141-9145 (1994) and induces regression of mammary and salivary carcinomas in *ras* transgenic mice (N.E. Kohl *et al.*, *Nature Medicine*, 1:792-797 (1995).

20 Indirect inhibition of farnesyl-protein transferase *in vivo* has been demonstrated with lovastatin (Merck & Co., Rahway, NJ) and compactin (Hancock *et al.*, *ibid*; Casey *et al.*, *ibid*; Schafer *et al.*, *Science* 245:379 (1989)). These drugs inhibit HMG-CoA reductase, the rate limiting enzyme for the production of polyisoprenoids including
25 farnesyl pyrophosphate. Farnesyl-protein transferase utilizes farnesyl pyrophosphate to covalently modify the Cys thiol group of the Ras CAAX box with a farnesyl group (Reiss *et al.*, *Cell*, 62:81-88 (1990); Schaber *et al.*, *J. Biol. Chem.*, 265:14701-14704 (1990); Schafer *et al.*, *Science*, 249:1133-1139 (1990); Manne *et al.*, *Proc. Natl. Acad. Sci USA*, 87:7541-7545 (1990)). Inhibition of farnesyl pyrophosphate
30 biosynthesis by inhibiting HMG-CoA reductase blocks Ras membrane localization in cultured cells. However, direct inhibition of farnesyl-protein transferase would be more specific and attended by fewer side effects than would occur with the required dose of a general inhibitor

- 3 -

of isoprene biosynthesis.

Inhibitors of farnesyl-protein transferase (FPTase) have been described in four general classes (S. Graham, *Expert Opinion Ther. Patents*, (1995) 5:1269-1285). The first are analogs of farnesyl diphosphate (FPP), while a second class of inhibitors is related to the protein substrates (e.g., Ras) for the enzyme. Bisubstrate inhibitors and inhibitors of farnesyl-protein transferase that are non-competitive with the substrates have also been described. The peptide derived inhibitors that have been described are generally cysteine containing molecules that are related to the CAAX motif that is the signal for protein prenylation. (Schaber *et al.*, *ibid*; Reiss *et. al.*, *ibid*; Reiss *et al.*, *PNAS*, 88:732-736 (1991)). Such inhibitors may inhibit protein prenylation while serving as alternate substrates for the farnesyl-protein transferase enzyme, or may be purely competitive inhibitors (U.S. Patent 5,141,851, University of Texas; N.E. Kohl *et al.*, *Science*, 260:1934-1937 (1993); Graham, *et al.*, *J. Med. Chem.*, 37, 725 (1994)). In general, deletion of the thiol from a CAAX derivative has been shown to dramatically reduce the inhibitory potency of the compound. However, the thiol group potentially places limitations on the therapeutic application of FPTase inhibitors with respect to pharmacokinetics, pharmacodynamics and toxicity. Therefore, a functional replacement for the thiol is desirable.

It has recently been disclosed that certain tricyclic compounds which optionally incorporate a piperidine moiety are inhibitors of FPTase (WO 95/10514, WO 95/10515 and WO 95/10516). Imidazole-containing inhibitors of farnesyl protein transferase have also been disclosed (WO 95/09001 and EP 0 675 112 A1).

It has recently been reported that farnesyl-protein transferase inhibitors are inhibitors of proliferation of vascular smooth muscle cells and are therefore useful in the prevention and therapy of arteriosclerosis and diabetic disturbance of blood vessels (JP H7-112930).

It is, therefore, an object of this invention to develop


- 4 -

low molecular weight compounds that will inhibit farnesyl-protein transferase and thus, the post-translational farnesylation of proteins. It is a further object of this invention to develop chemotherapeutic compositions containing the compounds of this invention and methods for producing the compounds of this invention.

SUMMARY OF THE INVENTION

The present invention comprises biheteroaryl-containing compounds which inhibit the farnesyl-protein transferase. Further contained in this invention are chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production.

The compounds of this invention are illustrated by the formula A:




A

- 5 -

DETAILED DESCRIPTION OF THE INVENTION

The compounds of this invention are useful in the inhibition of farnesyl-protein transferase and the farnesylation of the oncogene protein Ras. In a first embodiment of this invention, the inhibitors of farnesyl-protein transferase are illustrated by the formula A:



A

wherein:

a is N or C;

10

from 0-4 of b, c, d and e are independently N, NH, O and S, and the remaining b, c, d and e atoms are independently CH, provided that if a is C, then at least one of b, c, d or e is independently N, NH, O or S;

15 from 1-2 of f(s) are independently N, and the remaining f's are independently CH;

R¹ and R² are independently selected from:

- 20 a) hydrogen,
b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹⁰O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, R¹¹C(O)O-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,

- 6 -

- 5 c) unsubstituted or substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹⁰O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;

R³, R⁴ and R⁵ are independently selected from:

- 10 a) hydrogen,
 b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹¹C(O)O-,
 15 R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
 c) unsubstituted C₁-C₆ alkyl,
 d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic,
 20 C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;
 25 provided that when R³, R⁴ or R⁵ is unsubstituted or substituted heterocycle, attachment of R³, R⁴ or R⁵ to the six-membered heteroaryl ring is through a substitutable heterocycle ring carbon;

30 R^{6a}, R^{6b}, R^{6c} and R^{6d} are independently selected from:

- a) hydrogen,
 b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-,


- 7 -

$R^{11}S(O)_m-$, $R^{10}C(O)NR^{10}-$, $(R^{10})_2NC(O)-$, $R^{11}C(O)O-$,
 $R^{10}_2N-C(NR^{10})-$, CN, NO₂, $R^{10}C(O)-$, N₃, $-N(R^{10})_2$,
 or $R^{11}OC(O)NR^{10}-$,

- 5 c) unsubstituted C₁-C₆ alkyl,
 d) substituted C₁-C₆ alkyl wherein the substituent on the
 substituted C₁-C₆ alkyl is selected from unsubstituted or
 substituted aryl, unsubstituted or substituted heterocyclic,
 C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,
 $R^{12}O-$, $R^{11}S(O)_m-$, $R^{10}C(O)NR^{10}-$, $(R^{10})_2NC(O)-$,
 10 $R^{10}_2N-C(NR^{10})-$, CN, $R^{10}C(O)-$, N₃, $-N(R^{10})_2$, and
 $R^{11}OC(O)-NR^{10}-$;

R^7 is selected from: H; C₁-4 alkyl, C₃-6 cycloalkyl, heterocycle, aryl,
 aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or
 15 substituted with:

- a) C₁-4 alkoxy,
 b) aryl or heterocycle,
 c) halogen,
 d) HO,



- 20 f) $-SO_2R^{11}$
 g) $N(R^{10})_2$ or
 h) C₁-4 perfluoroalkyl;

R^8 is independently selected from:

- 25 a) hydrogen,
 b) aryl, substituted aryl, heterocycle, C₃-C₁₀ cycloalkyl,
 C₂-C₆ alkenyl, C₂-C₆ alkynyl, perfluoroalkyl, F, Cl, Br,
 $R^{10}O-$, $R^{11}S(O)_m-$, $R^{10}C(O)NR^{10}-$, $(R^{10})_2NC(O)-$,
 $R^{10}_2N-C(NR^{10})-$, CN, NO₂, $R^{10}C(O)-$, N₃, $-N(R^{10})_2$, or
 30 $R^{11}OC(O)NR^{10}-$, and

- 8 -

- 5 c) C₁-C₆ alkyl unsubstituted or substituted by aryl, cyanophenyl, heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, perfluoroalkyl, F, Cl, Br, R¹⁰O-, R¹¹S(O)_m-, R¹⁰C(O)NH-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹⁰OC(O)NH-;
- provided that when R⁸ is heterocycle, attachment of R⁸ to V is through a substitutable ring carbon;

10 R⁹ is independently selected from:

- a) hydrogen,
- b) C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, Br, R¹¹O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-, and
- 15 c) C₁-C₆ alkyl unsubstituted or substituted by perfluoroalkyl, F, Cl, Br, R¹⁰O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-;

20 R¹⁰ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl, 2,2,2-trifluoroethyl and aryl;

R¹¹ is independently selected from C₁-C₆ alkyl and aryl;

25 R¹² is independently selected from hydrogen, C₁-C₆ alkyl, C₁-C₆ aralkyl, C₁-C₆ substituted aralkyl, C₁-C₆ heteroaralkyl, C₁-C₆ substituted heteroaralkyl, aryl, substituted aryl, heteroaryl, substituted heteraryl, C₁-C₆ perfluoroalkyl, 2-aminoethyl and 2,2,2-trifluoroethyl;

30

A¹ and A² are independently selected from: a bond, -CH=CH-, -C≡C-, -C(O)-, -C(O)NR¹⁰-, -NR¹⁰C(O)-, O, -N(R¹⁰)-, -S(O)₂N(R¹⁰)-, -N(R¹⁰)S(O)₂-, or S(O)_m;

- 9 -

V is selected from:

- a) hydrogen,
- b) heterocycle,
- 5 c) aryl,
- d) C₁-C₂₀ alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and
- e) C₂-C₂₀ alkenyl,

provided that V is not hydrogen if A¹ is S(O)_m and V is not hydrogen
 10 if A¹ is a bond, n is 0 and A² is S(O)_m;
 provided that when V is heterocycle, attachment of V to R⁸ and to A¹ is through a substitutable ring carbon;

W is a heterocycle;

15

X is a bond, -CH=CH-, O, -C(=O)-, -C(O)NR⁷-, -NR⁷C(O)-, -C(O)O-,
 -OC(O)-, -C(O)NR⁷C(O)-, -NR⁷-, -S(O)₂N(R¹⁰)-, -N(R¹⁰)S(O)₂- or
 -S(=O)_m-;

20 m is 0, 1 or 2;

n is independently 0, 1, 2, 3 or 4;

p is independently 0, 1, 2, 3 or 4;

q is 0, 1, 2 or 3;


r is 0 to 5, provided that r is 0 when V is hydrogen; and

25 t is 0 or 1;

or the pharmaceutically acceptable salts thereof.

A preferred embodiment of the compounds of this invention is illustrated by the following formula A:

- 10 -



wherein:

a is N or C;

5

from 0-4 of b, c, d and e are independently N, NH, O and S, and the remaining b, c, d and e atoms are independently CH, provided that if a is C, then at least one of b, c, d or e is independently N, NH, O or S;

10 from 1-2 of f(s) are independently N, and the remaining f's are independently CH;

R¹ is independently selected from: hydrogen, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂, F or C₁-C₆ alkyl;

15

R² is independently selected from:

- a) hydrogen,
- b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂, F or C₂-C₆ alkenyl,
- 20 c) unsubstituted or substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, R¹⁰O- and -N(R¹⁰)₂;

25 R³, R⁴ and R⁵ are independently selected from:

- 11 -

- 5
- a) hydrogen,
 - b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
 - c) unsubstituted C₁-C₆ alkyl;
 - d) substituted C₁-C₆ alkyl wherein the substituent on the
- 10
- substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and
- 15
- R¹¹OC(O)-NR¹⁰-;

provided that when R³, R⁴ or R⁵ is unsubstituted or substituted heterocycle, attachment of R³, R⁴ or R⁵ to the six-membered heteroaryl ring is through a substitutable heterocycle ring carbon;

20

R^{6a}, R^{6b}, R^{6c} and R^{6d} are independently selected from:


- a) hydrogen,
 - b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
 - c) unsubstituted C₁-C₆ alkyl;
 - d) substituted C₁-C₆ alkyl wherein the substituent on the
- 25
- substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-, R¹¹S(O)_m-,
- 30

- 12 -

$R^{10}C(O)NR^{10}$ -, $(R^{10})_2NC(O)$ -, $R^{10}_2N-C(NR^{10})$ -, CN,
 $R^{10}C(O)$ -, N_3 -, $-N(R^{10})_2$, and $R^{11}OC(O)-NR^{10}$ -;

5 R^7 is selected from: H; C₁-4 alkyl, C₃-6 cycloalkyl, heterocycle, aryl,
 aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or
 substituted with:

- 10 a) C₁-4 alkoxy,
 b) aryl or heterocycle,
 c) halogen,
 d) HO,



- f) $-SO_2R^{11}$
 g) $N(R^{10})_2$ or
 h) C₁-4 perfluoroalkyl;

15 R^8 is independently selected from:

- a) hydrogen,
 b) aryl, substituted aryl, heterocycle, C₁-C₆ alkyl, C₂-C₆
 alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl,
 20 $R^{10}O$ -, $R^{10}C(O)NR^{10}$ -, CN, NO₂, $(R^{10})_2N-C(NR^{10})$ -,
 $R^{10}C(O)$ -, $-N(R^{10})_2$, or $R^{11}OC(O)NR^{10}$ -, and
 c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, $R^{10}O$ -,
 $R^{10}C(O)NR^{10}$ -, $(R^{10})_2N-C(NR^{10})$ -, $R^{10}C(O)$ -,
 $-N(R^{10})_2$, or $R^{11}OC(O)NR^{10}$ -;

25 provided that when R^8 is heterocycle, attachment of R^8 to V is
 through a substitutable ring carbon;

R^9 is selected from:

- a) hydrogen,
 b) C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F,
 30 Cl, $R^{11}O$ -, $R^{11}S(O)_m$ -, $R^{10}C(O)NR^{10}$ -, $(R^{10})_2NC(O)$ -,

- 13 -

CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-, and

- 5 c) C₁-C₆ alkyl unsubstituted or substituted by C₁-C₆ perfluoroalkyl, F, Cl, R¹⁰O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, CN, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-;

R¹⁰ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl, 2,2,2-trifluoroethyl and aryl;

10

R¹¹ is independently selected from C₁-C₆ alkyl and aryl;

R¹² is independently selected from hydrogen, C₁-C₆ alkyl, C₁-C₆ aralkyl, C₁-C₆ substituted aralkyl, C₁-C₆ heteroaralkyl, C₁-C₆ substituted heteroaralkyl, aryl, substituted aryl, heteroaryl, substituted heteraryl, C₁-C₆ perfluoroalkyl, 2-aminoethyl and 2,2,2-trifluoroethyl;

15

A¹ and A² are independently selected from: a bond, -CH=CH-, -C≡C-, -C(O)-, -C(O)NR¹⁰-, O, -N(R¹⁰)-, or S(O)_m;

20

V is selected from:

- a) hydrogen,
 b) heterocycle selected from pyrrolidinyl, imidazolyl, 25 imidazolinyl, pyridinyl, thiazolyl, oxazolyl, indolyl, quinolinyl, isoquinolinyl, triazolyl and thienyl,
 c) aryl,
 d) C₁-C₂₀ alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and
 e) C₂-C₂₀ alkenyl, and

30

provided that V is not hydrogen if A¹ is S(O)_m and V is not hydrogen if A¹ is a bond, n is 0 and A² is S(O)_m;

provided that when V is heterocycle, attachment of V to R⁸ and to A¹ is through a substitutable ring carbon;

- 14 -

W is a heterocycle selected from pyrrolidinyl, imidazolyl, imidazoliny, pyridinyl, thiazolyl, oxazolyl, indolyl, quinolinyl, triazolyl or isoquinolinyl;

5

X is a bond, O, -C(=O)-, -CH=CH-, -C(O)NR⁷-, -NR⁷C(O)-, -NR⁷-, -S(O)₂N(R¹⁰)-, -N(R¹⁰)S(O)₂- or -S(=O)_m-;

m is 0, 1 or 2;

10 n is independently 0, 1, 2, 3 or 4;

p is independently 0, 1, 2, 3 or 4;

q is 0, 1, 2 or 3;


r is 0 to 5, provided that r is 0 when V is hydrogen; and

t is 0 or 1;

15

or the pharmaceutically acceptable salts thereof.

A preferred embodiment of the compounds of this invention are illustrated by the formula B:



20 wherein:

a is N or C;

from 0-4 of b, c, d and e are independently N, NH, O and S, and the remaining b, c, d and e atoms are independently CH, provided that if a is C, then at least one of b, c, d or e is independently N, NH, O or S;

25

- 15 -

from 1-2 of f(s) are independently N, and the remaining f's are independently CH;

- 5 R^1 is independently selected from: hydrogen, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂, F or C₁-C₆ alkyl;

R^2 is independently selected from:

- 10 a) hydrogen,
b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂, F or C₂-C₆ alkenyl,
c) unsubstituted or substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, heterocycle, C₃-C₁₀
15 cycloalkyl, C₂-C₆ alkenyl, R¹⁰O- and -N(R¹⁰)₂;

R^3 and R^4 are independently selected from:

- a) hydrogen,
20 b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
25 c) unsubstituted C₁-C₆ alkyl,
d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,
30 R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;

provided that when R^3 or R^4 is unsubstituted or substituted heterocycle, attachment of R^3 or R^4 to the six-membered

- 16 -

heteroaryl ring is through a substitutable heterocycle ring carbon;

R^{6a}, R^{6b}, R^{6c} and R^{6d} are independently selected from:

- 5 a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
- 10 c) unsubstituted C₁-C₆ alkyl,
- d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;

20

R⁸ is independently selected from:

- a) hydrogen,
- b) aryl, substituted aryl, heterocycle, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-, and
- 25 c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-;

30

provided that when R⁸ is heterocycle, attachment of R⁸ to V is through a substitutable ring carbon;

R^{9a} and R^{9b} are independently hydrogen, C₁-C₆ alkyl, trifluoromethyl and halogen;

- 17 -

R¹⁰ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl, 2,2,2-trifluoroethyl and aryl;

5 R¹¹ is independently selected from C₁-C₆ alkyl and aryl;

R¹² is independently selected from hydrogen, C₁-C₆ alkyl, C₁-C₆ aralkyl, C₁-C₆ substituted aralkyl, C₁-C₆ heteroaralkyl, C₁-C₆ substituted heteroaralkyl, aryl, substituted aryl, heteroaryl, substituted heteraryl, C₁-C₆ perfluoroalkyl, 2-aminoethyl and 2,2,2-trifluoroethyl;

A¹ and A² are independently selected from: a bond, -CH=CH-, -C≡C-, -C(O)-, -C(O)NR¹⁰-, O, -N(R¹⁰)-, or S(O)_m;

15

V is selected from:

- a) hydrogen,
- b) heterocycle selected from pyrrolidinyl, imidazolyl, imidazolinyl, pyridinyl, thiazolyl, oxazolyl, indolyl, quinolinyl, isoquinolinyl, triazolyl and thienyl,
- c) aryl,
- d) C₁-C₂₀ alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and
- e) C₂-C₂₀ alkenyl, and

25 provided that V is not hydrogen if A¹ is S(O)_m and V is not hydrogen if A¹ is a bond, n is 0 and A² is S(O)_m;

provided that when V is heterocycle, attachment of V to R⁸ and to A¹ is through a substitutable ring carbon;

30 X is a bond, -CH=CH-, -C(O)NR¹⁰-, -NR¹⁰C(O)-, -NR¹⁰-, O or -C(=O)-;

m is 0, 1 or 2;


n is independently 0, 1, 2, 3 or 4;

- 18 -

p is 0, 1, 2, 3 or 4; and
 r is 0 to 5, provided that r is 0 when V is hydrogen;

or the pharmaceutically acceptable salts thereof.

5 Another preferred embodiment of the compounds of this invention are illustrated by the formula C:



wherein:

10 a is N or C;

from 0-4 of b, c, d and e are independently N, NH, O and S, and the remaining b, c, d and e atoms are independently CH, provided that if a is C, then at least one of b, c, d or e is independently N, NH, O or S;

15

from 1-2 of f(s) are independently N, and the remaining f's are independently CH;

R¹ is independently selected from: hydrogen, C₃-C₁₀ cycloalkyl,

20 R¹⁰O-, -N(R¹⁰)₂, F or C₁-C₆ alkyl;

R² is independently selected from:

a) hydrogen,

- b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂,
 25 F or C₂-C₆ alkenyl,

- 19 -

- c) unsubstituted or substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, R¹⁰O- and -N(R¹⁰)₂;

5

R³ and R⁴ are independently selected from:

- a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, CN(R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
- c) unsubstituted C₁-C₆ alkyl,
- d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;

10

15

20

provided that when R³ or R⁴ is unsubstituted or substituted heterocycle, attachment of R³ or R⁴ to the six-membered heteroaryl ring is through a substitutable heterocycle ring carbon;

25

R^{6a}, R^{6b}, R^{6c} and R^{6d} are independently selected from:

- a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, CN(R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,

30

- 20 -

- c) unsubstituted C₁-C₆ alkyl,
 d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl,
 5 C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-, R¹¹S(O)_m-,
 R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN,
 R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;

R⁸ is independently selected from:

- 10 a) hydrogen,
 b) aryl, substituted aryl, heterocycle, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-, and
 15 c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-;

provided that when R⁸ is heterocycle, attachment of R⁸ to V is through a substitutable ring carbon;

20 R^{9a} and R^{9b} are independently hydrogen, C₁-C₆ alkyl, trifluoromethyl and halogen;

25 R¹⁰ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl, 2,2,2-trifluoroethyl and aryl;

R¹¹ is independently selected from C₁-C₆ alkyl and aryl;

30 R¹² is independently selected from hydrogen, C₁-C₆ alkyl, C₁-C₆ aralkyl, C₁-C₆ substituted aralkyl, C₁-C₆ heteroaralkyl, C₁-C₆ substituted heteroaralkyl, aryl, substituted aryl, heteroaryl, substituted heteraryl, C₁-C₆ perfluoroalkyl, 2-aminoethyl and 2,2,2-trifluoroethyl;

- 21 -

A¹ and A² are independently selected from: a bond, -CH=CH-, -C≡C-, -C(O)-, -C(O)NR¹⁰-, O, -N(R¹⁰)-, or S(O)_m;

V is selected from:

- 5 a) hydrogen,
- b) heterocycle selected from pyrrolidinyl, imidazolyl, imidazolinyl, pyridinyl, thiazolyl, oxazolyl, indolyl, quinolinyl, isoquinolinyl, triazolyl and thienyl,
- c) aryl,
- 10 d) C₁-C₂₀ alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and
- e) C₂-C₂₀ alkenyl, and

provided that V is not hydrogen if A¹ is S(O)_m and V is not hydrogen if A¹ is a bond, n is 0 and A² is S(O)_m;

- 15 provided that when V is heterocycle, attachment of V to R⁸ and to A¹ is through a substitutable ring carbon;

X is a bond, -CH=CH-, -C(O)NR¹⁰-, -NR¹⁰C(O)-, -NR¹⁰-, O or -C(=O)-;

20

m is 0, 1 or 2;

n is independently 0, 1, 2, 3 or 4;

p is 0, 1, 2, 3 or 4, provided that p is not 0 if X is a bond or O; and


- 25 r is 0 to 5, provided that r is 0 when V is hydrogen;

or the pharmaceutically acceptable salts thereof.

In a more preferred embodiment of this invention, the inhibitors of farnesyl-protein transferase are illustrated by the formula

30 D:

- 22 -



wherein:

a is N or C;

5

from 0-4 of b, c, d and e are independently N, NH, O and S, and the remaining b, c, d and e atoms are independently CH, provided that if a is C, then at least one of b, c, d or e is independently N, NH, O or S;

10 from 1-2 of f(s) are independently N, and the remaining f's are independently CH;

R¹ is independently selected from: hydrogen, C₃-C₁₀ cycloalkyl or C₁-C₆ alkyl;

15

R² is independently selected from:

- a) hydrogen,
- b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂, F or C₂-C₆ alkenyl,
- 20 c) C₁-C₆ alkyl unsubstituted or substituted by aryl, heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, R¹⁰O-, or -N(R¹⁰)₂;

- R³ is selected from:

25

- a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆

- 23 -

- alkenyl, C2-C6 alkynyl, halogen, C1-C6 perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
- 5 c) unsubstituted C1-C6 alkyl,
- d) substituted C1-C6 alkyl wherein the substituent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl,
- 10 R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;
- provided that when R³ is unsubstituted or substituted heterocycle, attachment of R³ to the six-membered heteroaryl ring is
- 15 through a substitutable heterocycle ring carbon;

R⁴ is selected from H, halogen, C1-C6 alkyl and CF₃;

R^{6a}, R^{6b}, R^{6c} and R^{6d} are independently selected from:

- 20 a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, C1-C6 perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-,
- 25 R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
- c) unsubstituted C1-C6 alkyl,
- d) substituted C1-C6 alkyl wherein the substituent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl,
- 30 R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;

- 24 -

R^8 is independently selected from:

- a) hydrogen,
- b) aryl, substituted aryl, heterocycle, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 perfluoroalkyl, F, Cl, $R^{10}O$ -, $R^{10}C(O)NR^{10}$ -, CN, NO_2 , $(R^{10})_2N-C(NR^{10})$ -, $R^{10}C(O)$ -, $-N(R^{10})_2$, or $R^{11}OC(O)NR^{10}$ -, and
- c) C_1 - C_6 alkyl substituted by C_1 - C_6 perfluoroalkyl, $R^{10}O$ -, $R^{10}C(O)NR^{10}$ -, $(R^{10})_2N-C(NR^{10})$ -, $R^{10}C(O)$ -, $-N(R^{10})_2$, or $R^{11}OC(O)NR^{10}$ -;

provided that when R^8 is heterocycle, attachment of R^8 to V is through a substitutable ring carbon;

R^{9a} and R^{9b} are independently hydrogen, ethyl, cyclopropyl or methyl;

R^{10} is independently selected from hydrogen, C_1 - C_6 alkyl, benzyl, 2,2,2-trifluoroethyl and aryl;

R^{11} is independently selected from C_1 - C_6 alkyl and aryl;

R^{12} is independently selected from hydrogen, C_1 - C_6 alkyl, C_1 - C_6 aralkyl, C_1 - C_6 substituted aralkyl, C_1 - C_6 heteroaralkyl, C_1 - C_6 substituted heteroaralkyl, aryl, substituted aryl, heteroaryl, substituted heteraryl, C_1 - C_6 perfluoroalkyl, 2-aminoethyl and 2,2,2-trifluoroethyl;

A^1 is selected from: a bond, $-C(O)$ -, O, $-N(R^{10})$ -, or $S(O)_m$;

X is a bond, $-CH=CH-$, $-C(O)NR^{10}$ -, $-NR^{10}C(O)$ -, $-NR^{10}$ -, O or $-C(=O)$ -;


n is 0 or 1;
m is 0, 1 or 2; and
p is 0, 1, 2, 3 or 4;

- 25 -

or the pharmaceutically acceptable salts thereof.

In another more preferred embodiment of this invention,
the inhibitors of farnesyl-protein transferase are illustrated by the

5 formula E:



wherein:

a is N or C;

10

from 0-4 of b, c, d and e are independently N, NH, O and S, and the
remaining b, c, d and e atoms are independently CH, provided that if a
is C, then at least one of b, c, d or e is independently N, NH, O or S;

15 from 1-2 of f(s) are independently N, and the remaining f's are
independently CH;

R¹ is independently selected from: hydrogen, C₃-C₁₀ cycloalkyl,
R¹⁰O-, -N(R¹⁰)₂, F or C₁-C₆ alkyl;

20

R² is independently selected from:

- a) hydrogen,
- b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂,
F or C₂-C₆ alkenyl,

- 26 -

- c) C₁-C₆ alkyl unsubstituted or substituted by aryl, heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, R¹⁰O-, or -N(R¹⁰)₂;

5 R³ is selected from:

- a) hydrogen,
 b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
 c) unsubstituted C₁-C₆ alkyl,
 d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;
 provided that when R³ is unsubstituted or substituted heterocycle, attachment of R³ to the six-membered heteroaryl ring is through a substitutable heterocycle ring carbon;

25 R⁴ is selected from H, halogen, C₁-C₆ alkyl and CF₃;

R^{6a}, R^{6b}, R^{6c} and R^{6d} are independently selected from:

- a) hydrogen,
 b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,

- 27 -

- 5 c) unsubstituted C₁-C₆ alkyl,
 d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;

10 R⁸ is independently selected from:

- a) hydrogen,
 b) aryl, substituted aryl, heterocycle, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-, and
 15 c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-;

20 provided that when R⁸ is heterocycle, attachment of R⁸ to V is through a substitutable ring carbon;

R^{9a} and R^{9b} are independently hydrogen, ethyl, cyclopropyl or methyl;

25 R¹⁰ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl, 2,2,2-trifluoroethyl and aryl;

R¹¹ is independently selected from C₁-C₆ alkyl and aryl;

30 R¹² is independently selected from hydrogen, C₁-C₆ alkyl, C₁-C₆ aralkyl, C₁-C₆ substituted aralkyl, C₁-C₆ heteroaralkyl, C₁-C₆ substituted heteroaralkyl, aryl, substituted aryl, heteroaryl, substituted heteraryl, C₁-C₆ perfluoroalkyl, 2-aminoethyl and 2,2,2-trifluoroethyl;


- 28 -

X is a bond, -CH=CH-, -C(O)NR¹⁰-, -NR¹⁰C(O)-, -NR¹⁰-, O or -C(=O)-;

- n is 0 or 1; provided that n is not 0 if A¹ is a bond, O,
 5 -N(R¹⁰)-, or S(O)_m;
 m is 0, 1 or 2; and
 p is 0, 1, 2, 3 or 4, provided that p is not 0 if X is a bond or O;

or the pharmaceutically acceptable salts thereof.

- 10 In a further embodiment of this invention, the inhibitors of farnesyl-protein transferase are illustrated by the formula F:



wherein:

- 15 a is N or C;
 from 0-4 of b, c, d and e are independently N, NH, O and S, and the remaining b, c, d and e atoms are independently CH, provided that if a is C, then at least one of b, c, d or e is independently N, NH, O or S;
 20 from 1-2 of f(s) are independently N, and the remaining f's are independently CH;
 R¹ is independently selected from: hydrogen, C₃-C₁₀ cycloalkyl or
 25 C₁-C₆ alkyl;

- 29 -

R² is independently selected from:

- a) hydrogen,
- b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂ or F,
- 5 c) C₁-C₆ alkyl unsubstituted or substituted by aryl, heterocycle, C₃-C₁₀ cycloalkyl, R¹⁰O-, or -N(R¹⁰)₂;

R³ is selected from:

- a) hydrogen,
- 10 b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
- 15 c) unsubstituted C₁-C₆ alkyl,
- d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;
- 20
- 25 provided that when R³ is unsubstituted or substituted heterocycle, attachment of R³ to the six-membered heteroaryl ring is through a substitutable heterocycle ring carbon;

R⁴ is selected from H, halogen, CH₃ and CF₃;

30 R^{6a}, R^{6b}, R^{6c} and R^{6d} are independently selected from:

- a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆


- 30 -

- alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
- 5 c) unsubstituted C₁-C₆ alkyl,
- d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,
- 10 R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;
- R^{9a} and R^{9b} are independently hydrogen, ethyl, cyclopropyl or methyl;
- 15 R¹⁰ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl, 2,2,2-trifluoroethyl and aryl;
- R¹¹ is independently selected from C₁-C₆ alkyl and aryl;
- 20 R¹² is independently selected from hydrogen, C₁-C₆ alkyl, C₁-C₆ aralkyl, C₁-C₆ substituted aralkyl, C₁-C₆ heteroaralkyl, C₁-C₆ substituted heteroaralkyl, aryl, substituted aryl, heteroaryl, substituted heteraryl, C₁-C₆ perfluoroalkyl,
- 25 2-aminoethyl and 2,2,2-trifluoroethyl;
- X is a bond, -CH=CH-, -C(O)NR¹⁰-, -NR¹⁰C(O)-, -NR¹⁰-, O or -C(=O)-;
- 30 m is 0, 1 or 2; and
- p is 0, 1, 2, 3 or 4;

or the pharmaceutically acceptable salts thereof.

- 31 -

In a further embodiment of this invention, the inhibitors of farnesyl-protein transferase are illustrated by the formula G:



wherein:

5

a is N or C;

from 0-4 of b, c, d and e are independently N, NH, O and S, and the remaining b, c, d and e atoms are independently CH, provided that if a is C, then at least one of b, c, d or e is independently N, NH, O or S;

10

from 1-2 of f(s) are independently N, and the remaining f's are independently CH;

15 R^1 is independently selected from: hydrogen, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂, F or C₁-C₆ alkyl;

R^2 is independently selected from:

- 20 a) hydrogen,
b) aryl or heterocycle,
c) C₁-C₆ alkyl unsubstituted or substituted by aryl, heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, R¹⁰O-, or -N(R¹⁰)₂;

25 R^3 is selected from:

- a) hydrogen,

- 32 -

- 5 b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
- 10 c) unsubstituted C₁-C₆ alkyl,
- d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;
- 15 provided that when R³ is unsubstituted or substituted heterocycle, attachment of R³ to the six-membered heteroaryl ring is through a substitutable heterocycle ring carbon;
- 20 R⁴ is selected from H, halogen, CH₃ and CF₃;
- R^{6a}, R^{6b}, R^{6c} and R^{6d} are independently selected from:
- 25 a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
- 30 c) unsubstituted C₁-C₆ alkyl,
- d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,


- 33 -

$R^{12}O-$, $R^{11}S(O)_m-$, $R^{10}C(O)NR^{10}-$, $(R^{10})_2NC(O)-$,
 $R^{10}_2N-C(NR^{10})-$, CN , $R^{10}C(O)-$, N_3 , $-N(R^{10})_2$, and
 $R^{11}OC(O)-NR^{10}-$;

- 5 R^{9a} and R^{9b} are independently hydrogen, ethyl, cyclopropyl or methyl;
 R^{10} is independently selected from hydrogen, C_1 - C_6 alkyl, benzyl,
 2,2,2-trifluoroethyl and aryl;
- 10 R^{11} is independently selected from C_1 - C_6 alkyl and aryl;
 R^{12} is independently selected from hydrogen, C_1 - C_6 alkyl, C_1 - C_6
 aralkyl, C_1 - C_6 substituted aralkyl, C_1 - C_6 heteroaralkyl,
 C_1 - C_6 substituted heteroaralkyl, aryl, substituted aryl,
 15 heteroaryl, substituted heteraryl, C_1 - C_6 perfluoroalkyl,
 2-aminoethyl and 2,2,2-trifluoroethyl;
- A^1 is selected from: a bond, $-C(O)-$, O , $-N(R^{10})-$, or $S(O)_m$;
- 20 m is 0, 1 or 2; and
 n is 0 or 1;
- or the pharmaceutically acceptable salts thereof.


- 25 Specific examples of the compounds of the invention are:

1-(2-[Thien-2-yl]pyrid-5-ylmethyl)-5-(4-cyanobenzyl)imidazole.



- 34 -

N-{1-(4-Cyanobenzyl)-1H-imidazol-5-yl)methyl}-5-(thien-2-yl)-2-amino-pyrimidine



5

or the pharmaceutically acceptable salts thereof.

The compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention. When any variable (e.g. aryl, heterocycle, R¹, R² etc.) occurs more than one time in any constituent, its definition on each occurrence is independent at every other occurrence. Also, combinations of substituents/or variables are permissible only if such combinations result in stable compounds.

15 As used herein, "alkyl" and the alkyl portion of aralkyl and similar terms, is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms; "alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge.

20 As used herein, "cycloalkyl" is intended to include non-aromatic cyclic hydrocarbon groups having the specified number of carbon atoms. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.

"Alkenyl" groups include those groups having the specified number of carbon atoms and having one or several double bonds. Examples of alkenyl groups include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, isoprenyl, farnesyl, geranyl, geranylgeranyl and the like.

- 35 -

"Alkynyl" groups include those groups having the specified number of carbon atoms and having one triple bonds. Examples of alkynyl groups include acetylene, 2-butylnyl, 2-pentylnyl, 3-pentylnyl and the like.

5 "Halogen" or "halo" as used herein means fluoro, chloro, bromo and iodo.

As used herein, "aryl," and the aryl portion of aralkyl and aroyl, is intended to mean any stable monocyclic or bicyclic carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic.
10 Examples of such aryl elements include phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthryl, anthryl or acenaphthyl.

The term heterocycle or heterocyclic, as used herein, represents a stable 5- to 7-membered monocyclic or stable 8- to 11-membered bicyclic heterocyclic ring which is either saturated or
15 unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the
20 creation of a stable structure. Examples of such heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnoliny, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl,
25 dihydrobenzothiopyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indoliny, indolyl, isochromanyl, isoindoliny, isoquinoliny, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholiny, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, 2-oxopyrrolidinyl, pyridyl, pyrazinyl, pyrazolidinyl, pyrazolyl,
30 pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinazolinyl, quinoliny, quinoxaliny, tetrahydrofuryl, tetrahydroisoquinoliny, tetrahydroquinoliny, thiamorpholiny, thiamorpholiny sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, and thienyl.

- 36 -

As used herein, "heteroaryl" is intended to mean any stable monocyclic or bicyclic carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic and wherein from one to four carbon atoms are replaced by heteroatoms selected from the group consisting of N, O, and S. Examples of such heterocyclic elements include, but are not limited to, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnoliny, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, furyl, imidazolyl, indoliny, indolyl, isochromanyl, isoindoliny, isoquinoliny, isothiazolyl, naphthyridiny, oxadiazolyl, pyridyl, pyraziny, pyrazolyl, pyridaziny, pyrimidiny, pyrrolyl, quinazoliny, quinoliny, quinoxaliny, tetrahydroisoquinoliny, tetrahydroquinoliny, thiazolyl, thienofuryl, thienothienyl, and thienyl.

As used herein in the definition of R³, R⁴, R⁵ and R^{6a-d}, the term "the substituted group" intended to mean a substituted C₁₋₈ alkyl, substituted C₂₋₈ alkenyl, substituted C₂₋₈ alkynyl, substituted aryl or substituted heterocycle from which the substituent(s) R³, R⁴, R⁵ and R^{6a-e} are selected.

As used herein in the definition of R⁷, the substituted C₁₋₈ alkyl, substituted C₃₋₆ cycloalkyl, substituted aroyl, substituted aryl, substituted heteroaroyl, substituted arylsulfonyl, substituted heteroaryl-sulfonyl and substituted heterocycle include moieties containing from 1 to 3 substituents in addition to the point of attachment to the rest of the compound.


As used herein, when no specific substituents are set forth, the terms "substituted aryl", "substituted heterocycle" and "substituted cycloalkyl" are intended to include the cyclic group which is substituted on a substitutable ring carbon atom with 1 or 2 substituents selected from the group which includes but is not limited to F, Cl, Br, CF₃, NH₂, N(C₁-C₆ alkyl)₂, NO₂, CN, (C₁-C₆ alkyl)O-, -OH, (C₁-C₆ alkyl)S(O)_m-, (C₁-C₆ alkyl)C(O)NH-, H₂N-C(NH)-, (C₁-C₆ alkyl)

- 37 -






C(O)-, (C₁-C₆ alkyl)OC(O)-, N₃-(C₁-C₆ alkyl)OC(O)NH-, phenyl, pyridyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, isothiazolyl and C₁-C₂₀ alkyl.

- 5 Lines drawn into the ring systems from substituents (such as from R³, R⁴ etc.) means that the indicated bond may be attached to any of the substitutable ring carbon or nitrogen atoms.


The moiety designated by the following structure



- 10 represents an aromatic 6-membered heterocyclic ring and includes the following ring systems:




The moiety designated by the following structure




- 15 represents an aromatic 6-membered heterocyclic ring and includes the following ring systems:

- 38 -




wherein it is understood that one of the ring carbon atoms is substituted with




- 5 Preferably, the aromatic 6-membered heterocyclic ring is a pyridyl ring.

The moiety designated by the following structure




- 10 represents an aromatic 5-membered heterocyclic ring and includes the following ring systems:

- 39 -



Preferably the aromatic 5-membered heterocyclic ring is selected from:



- 5 Preferably, R^1 and R^2 are independently selected from:
hydrogen, $R^{11}C(O)O-$, $-N(R^{10})_2$, $R^{10}C(O)NR^{10}-$, $R^{10}O-$ or
unsubstituted or substituted C_1-C_6 alkyl wherein the substituent on the
substituted C_1-C_6 alkyl is selected from unsubstituted or substituted
phenyl, $-N(R^{10})_2$, $R^{10}O-$ and $R^{10}C(O)NR^{10}-$.

- 10 Preferably, R^3 is selected from:

a) hydrogen,

- 40 -

- b) C3-C10 cycloalkyl, halogen, C1-C6 perfluoroalkyl, R¹²O-, CN, NO₂, R¹⁰C(O)- or -N(R¹⁰)₂,
 c) unsubstituted C1-C6 alkyl,
 d) substituted C1-C6 alkyl wherein the substituent on the
 5 substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and
 10 R¹¹OC(O)-NR¹⁰-.

Preferably, R⁴ is selected from: hydrogen, halogen, trifluoromethyl, trifluoromethoxy and C1-C6 alkyl.

Preferably, R⁵ is hydrogen.

Preferably, R^{6a}, R^{6b}, R^{6c} and R^{6d} are independently
 15 selected from:

- a) hydrogen,
 b) C3-C10 cycloalkyl, halogen, C1-C6 perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, CN, NO₂, R¹⁰C(O)- or -N(R¹⁰)₂,
 c) unsubstituted C1-C6 alkyl;
 20 d) substituted C1-C6 alkyl wherein the substituent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, C3-C10 cycloalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)- or -N(R¹⁰)₂.

Preferably, R⁸ is independently selected from:

- 25 a) hydrogen, and
 b) aryl, substituted aryl, heterocycle, substituted heterocycle, C1-C6 perfluoroalkyl or CN.

Preferably, R⁹ is hydrogen, halogen or methyl.

Preferably, R¹⁰ is selected from H, C1-C6 alkyl and
 30 benzyl.

Preferably, A¹ and A² are independently selected from:
 a bond, -C(O)NR¹⁰-, -NR¹⁰C(O)-, O, -N(R¹⁰)-, -S(O)₂N(R¹⁰)- and
 N(R¹⁰)S(O)₂-.

- 41 -

Preferably, V is selected from hydrogen, heterocycle and aryl. More preferably, V is phenyl.

Preferably, W is selected from imidazolyl, imidazolyl, oxazolyl, pyrazolyl, pyrrolidyl, thiazolyl and pyridyl. More preferably, W is selected from imidazolyl and pyridyl.


Preferably, n and r are independently 0, 1, or 2.

Preferably s is 0.


Preferably t is 1.

Preferably from 1-2 of f(s) are independently N, and the remaining fs are independently CH.

Preferably, the moiety



is selected from:



It is intended that the definition of any substituent or variable (e.g., R¹, R², R⁹, n, etc.) at a particular location in a molecule be independent of its definitions elsewhere in that molecule. Thus, -N(R¹⁰)₂ represents -NHH, -NHCH₃, -NHC₂H₅, etc. It is understood that substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials.

- 42 -

The pharmaceutically acceptable salts of the compounds of this invention include the conventional non-toxic salts of the compounds of this invention as formed, e.g., from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those
5 derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pantoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy-benzoic,
10 fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like.

The pharmaceutically acceptable salts of the compounds of this invention can be synthesized from the compounds of this invention which contain a basic moiety by conventional chemical
15 methods. Generally, the salts are prepared either by ion exchange chromatography or by reacting the free base with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid in a suitable solvent or various combinations of solvents.

Reactions used to generate the compounds of this invention
20 are prepared by employing reactions as shown in the Schemes 1-22, in addition to other standard manipulations such as ester hydrolysis, cleavage of protecting groups, etc., as may be known in the literature or exemplified in the experimental procedures. Substituents R^3 , R^6 and R^8 , as shown in the Schemes, represent the substituents R^3 , R^4 ,
25 R^5 , R^{6a} , R^{6b} , R^{6c} , R^{6d} and R^8 ; although only one such R^3 , R^6 or R^8 is present in the intermediates and products of the schemes, it is understood that the reactions shown are also applicable when such aryl or heteroaryl moieties contain multiple substituents.

These reactions may be employed in a linear sequence
30 to provide the compounds of the invention or they may be used to synthesize fragments which are subsequently joined by the alkylation reactions described in the Schemes. The reactions described in the Schemes are illustrative only and are not meant to be limiting. Other reactions useful in the preparation of heteroaryl moieties are described

- 43 -

in "Comprehensive Organic Chemistry, Volume 4: Heterocyclic Compounds" ed. P.G. Sammes, Oxford (1979) and references therein. Aryl-aryl coupling is generally described in "Comprehensive Organic Functional Group Transformations," Katritzky et al. eds., pp 472-473, Pergamon Press (1995).

Synopsis of Schemes 1-22:

The requisite intermediates are in some cases commercially available, or can be prepared according to literature procedures, for the most part. Schemes 1- 13 illustrate synthesis of the instant biheteroaryl compound which incorporate a preferred benzylimidazolyl sidechain. Thus, in Scheme 1, for example, a biheteroaryl intermediate that is not commercially available may be synthesized by methods known in the art. Thus, a suitably substituted thienyl boronic acid I may be reacted under Suzuki coupling conditions (*Pure Appl. Chem.*, 63:419 (1991)) with a suitably substituted activated nicotinic acid, such as nicotinic acid 6-triflate, to provide the biheteroaryl carboxylic acid II. The acid may be reduced and the triflate of the intermediate alcohol III may be formed in situ and coupled to a suitably substituted benzylimidazolyl IV to provide, after deprotection, the instant compound V.

Schemes 2-5 illustrate other methods of synthesizing the key alcohol intermediates, which can then be processed as described in Scheme 1. Thus, Scheme 2 illustrates the reaction wherein the "terminal" 5-membered heteroaryl moiety is employed in the Suzuki coupling as the halogenated reactant. Such a coupling reaction is also compatible when one of the reactants incorporates a suitably protected hydroxyl functionality as illustrated in Scheme 3.

Negishi chemistry (*Org. Synth.*, 66:67 (1988)) may also be employed to form the biheteroaryl component of the instant compounds, as shown in Scheme 4. Thus, a suitably substituted zinc bromide adduct may be coupled to a suitably substituted heteroaryl halide in the presence of nickel (II) to provide the biheteroaryl VII. The heteroaryl halide and the zinc bromide adduct may be selected based on the availability of the starting reagents.

- 44 -

Scheme 5 illustrates the preparation of a suitably substituted biheteroaryl alcohol starting from the halogenated methylpyridine.

As illustrated in Scheme 6, the sequence of coupling reactions may be modified such that the biphenyl bond is formed last. Thus, a suitably substituted imidazole may first be alkylated with a suitably substituted benzyl halide to provide intermediate VIII. Intermediate VIII can then undergo Suzuki type coupling to a suitably substituted phenyl boronic acid.

Scheme 7 illustrates synthesis of an instant compound wherein a non-hydrogen R^{9b} is incorporated in the instant compound. Thus, a readily available 4-substituted imidazole IX may be selectively iodinated to provide the 5-iodoimidazole X. That imidazole may then be protected and coupled to a suitably substituted benzyl moiety to provide intermediate XI. Intermediate XI can then undergo the alkylation reactions that were described hereinabove.

Scheme 8 illustrates synthesis of instant compounds that incorporate a preferred imidazolyl moiety connected to the biheteroaryl via an alkyl amino, sulfonamide or amide linker. Thus, the 4-amino-alkylimidazole XII, wherein the primary amine is protected as the phthalimide, is selectively alkylated then deprotected to provide the amine XIII. The amine XIII may then react under conditions well known in the art with various activated biheteroaryl moieties to provide the instant compounds shown.

Use of another 6-member heteroaryl in the synthesis of the instant compounds is illustrated in Scheme 9. Thus, a halogenated 2-aminopyrimidine may be coupled with a heteroaryl boronic acid to provide the biheteroaryl amine XIIIa, which can then be reacted with the preferred imidazolylmethyl sidechain to provide the instant compound.

Compounds of the instant invention wherein the $A^1(CR^1_2)_nA^2(CR^1_2)_n$ linker is oxygen may be synthesized by methods known in the art, for example as shown in Scheme 10. The suitably substituted phenol XIV may be reacted with methyl N-(cyano)methanimidate to provide the 4-phenoxyimidazole XV.

- 45 -


After selective protection of one of the imidazolyl nitrogens, the intermediate XVI can undergo alkylation reactions as described for the benzylimidazoles hereinabove.

Scheme 11 illustrates an analogous series of reactions wherein the $(CR^2)_pX(CR^2)_p$ linker of the instant compounds is oxygen. Thus, a suitably substituted halopyridinol, such as , is reacted with methyl N-(cyano)methanimidate to provide intermediate XVI. Intermediate XVI is then protected and, if desired to form a compound of a preferred embodiment, alkylated with a suitably protected benzyl. The intermediate XVII can then be coupled to a heteroaryl moiety by Suzuki chemistry to provide the instant compound.


Compounds of the instant invention wherein the $A^1(CR^1)_nA^2(CR^1)_n$ linker is a substituted methylene may be synthesized by the methods shown in Scheme 12. Thus, the N-protected imidazolyl iodide XVIII is reacted, under Grignard conditions with a suitably protected benzaldehyde to provide the alcohol XIX. Acylation, followed by the alkylation procedure illustrated in the Schemes above (in particular, Scheme 1) provides the instant compound XX. If other R^1 substituents are desired, the acetyl moiety can be manipulated as illustrated in the Scheme.

Addition of various nucleophiles to an imidazolyl aldehyde may also be employed to form a substituted alkyl linker between the biheteroaryl and the preferred W (imidazolyl) as shown in Scheme 13. Thus a lithiothiophene can be reacted with pyridine to form the 2 substituted N-lithio-1,2-dihydropyridine XXa. Intermediate XXa can then react with an aldehyde to provide a suitably substituted instant compound. Similar substituent manipulation as shown in Scheme 12 may be performed on the fully functionalized compound which incorporates an R^2 hydroxyl moiety.


- 46 -

SCHEME 1


- 47 -

SCHEME I (continued)


- 48 -

SCHEME 2


- 49 -

SCHEME 3


- 50 -

SCHEME 4





- 51 -

SCHEME 5


- 52 -

SCHEME 6


- 53 -

SCHEME 7


- 54 -

SCHEME 8


- 55 -

SCHEME 9


- 56 -

SCHEME 10


- 57 -

SCHEME 11


- 58 -

SCHEME 12

- 59 -


SCHEME 12 (continued)

- 60 -

SCHEME 13

- 61 -

Schemes 14-20 illustrate reactions wherein the moiety



incorporated in the compounds of the instant invention is represented by
5 other than a substituted imidazole-containing group.

Thus, the intermediates whose synthesis are illustrated in
Schemes hereinabove and other biheteroaryl intermediates obtained
commercially or readily synthesized, can be coupled with a variety of
aldehydes. The aldehydes can be prepared by standard procedures, such
10 as that described by O. P. Goel, U. Krolls, M. Stier and S. Kesten in
Organic Syntheses, 1988, 67, 69-75, from the appropriate amino acid.
Lithioheteroaryl chemistry may be utilized, as shown in Scheme 14,
to incorporate the biheteroaryl moiety. Thus, a suitably substituted
biheteroaryl N-lithio reagent is reacted with an aldehyde to provide
15 the C-alkylated instant compound XXI. Compound XXI can be
deoxygenated by methods known in the art, such as a catalytic
hydrogenation, then deprotected with trifluoroacetic acid in methylene
chloride to give the final compound XXII. The final product XXII
may be isolated in the salt form, for example, as a trifluoroacetate,
20 hydrochloride or acetate salt, among others. The product diamine
XXII can further be selectively protected to obtain XXIII, which can
subsequently be reductively alkylated with a second aldehyde to obtain
XXIV. Removal of the protecting group, and conversion to cyclized
products such as the dihydroimidazole XXV can be accomplished by
25 literature procedures.

If the biheteroaryl subunit reagent is reacted with an
aldehyde which also has a protected hydroxyl group, such as XXVI
in Scheme 15, the protecting groups can be subsequently removed to
unmask the hydroxyl group (Schemes 15, 16). The alcohol can be
30 oxidized under standard conditions to e.g. an aldehyde, which can

- 62 -


then be reacted with a variety of organometallic reagents such as alkyl lithium reagents, to obtain secondary alcohols such as **XXX**. In addition, the fully deprotected amino alcohol **XXXI** can be reductively alkylated (under conditions described previously) with
5 a variety of aldehydes to obtain secondary amines, such as **XXXII** (Scheme 16), or tertiary amines.

The Boc protected amino alcohol **XXVIII** can also be utilized to synthesize 2-aziridinylmethylbiheteroaryl such as **XXXIII** (Scheme 17). Treating **XXVIII** with 1,1'-sulfonyldiimidazole and
10 sodium hydride in a solvent such as dimethylformamide led to the formation of aziridine **XXXIII**. The aziridine is reacted with a nucleophile, such as a thiol, in the presence of base to yield the ring-opened product **XXXIV**.




In addition, the biheteroaryl subunit reagent can be reacted
15 with aldehydes derived from amino acids such as O-alkylated tyrosines, according to standard procedures, to obtain compounds such as **XL**, as shown in Scheme 18. When R' is an aryl group, **XL** can first be hydrogenated to unmask the phenol, and the amine group deprotected with acid to produce **XLI**. Alternatively, the amine protecting group
20 in **XL** can be removed, and O-alkylated phenolic amines such as **XLII** produced.


Schemes 19-22 illustrate syntheses of suitably substituted aldehydes useful in the syntheses of the instant compounds wherein the variable W is present as a pyridyl moiety. Similar synthetic strategies
25 for preparing alkanols that incorporate other heterocyclic moieties for variable W are also well known in the art.

SCHEME 14




- 64 -


SCHEME 14 (continued)



- 66 -


SCHEME 15 (continued)

XXIX






XXX


- 67 -

SCHEME 16

- 68 -


SCHEME 17

- 69 -





SCHEME 18

- 70 -

SCHEME 18 (continued)




- 71 -


SCHEME 19

- 72 -


SCHEME 20



- 73 -

SCHEME 21

- 74 -

SCHEME 22

- 75 -

The instant compounds are useful as pharmaceutical agents for mammals, especially for humans. These compounds may be administered to patients for use in the treatment of cancer. Examples of the type of cancer which may be treated with the compounds of this invention include, but are not limited to, colorectal carcinoma, exocrine pancreatic carcinoma, myeloid leukemias and neurological tumors. Such tumors may arise by mutations in the *ras* genes themselves, mutations in the proteins that can regulate Ras activity (i.e., neurofibromin (NF-1), neu, scr, abl, lck, fyn) or by other mechanisms.

10 The compounds of the instant invention inhibit farnesyl-protein transferase and the farnesylation of the oncogene protein Ras. The instant compounds may also inhibit tumor angiogenesis, thereby affecting the growth of tumors (J. Rak et al. *Cancer Research*, 55:4575-4580 (1995)). Such anti-angiogenesis properties of the instant
15 compounds may also be useful in the treatment of certain forms of blindness related to retinal vascularization.

 The compounds of this invention are also useful for inhibiting other proliferative diseases, both benign and malignant, wherein Ras proteins are aberrantly activated as a result of oncogenic
20 mutation in other genes (i.e., the Ras gene itself is not activated by mutation to an oncogenic form) with said inhibition being accomplished by the administration of an effective amount of the compounds of the invention to a mammal in need of such treatment. For example, a component of NF-1 is a benign proliferative disorder.

25 The instant compounds may also be useful in the treatment of certain viral infections, in particular in the treatment of hepatitis delta and related viruses (J.S. Glenn et al. *Science*, 256:1331-1333 (1992)).

 The compounds of the instant invention are also useful in
30 the prevention of restenosis after percutaneous transluminal coronary angioplasty by inhibiting neointimal formation (C. Indolfi et al. *Nature medicine*, 1:541-545(1995)).

 The instant compounds may also be useful in the treatment and prevention of polycystic kidney disease (D.L. Schaffner et al.

- 76 -

American Journal of Pathology, 142:1051-1060 (1993) and B. Cowley, Jr. et al. *FASEB Journal*, 2:A3160 (1988)).

The instant compounds may also be useful for the treatment of fungal infections.

5 The compounds of this invention may be administered to mammals, preferably humans, either alone or, preferably, in combination with pharmaceutically acceptable carriers or diluents, optionally with known adjuvants, such as alum, in a pharmaceutical composition, according to standard pharmaceutical practice. The
10 compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.

For oral use of a chemotherapeutic compound according to this invention, the selected compound may be administered, for
15 example, in the form of tablets or capsules, or as an aqueous solution or suspension. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch, and lubricating agents, such as magnesium stearate, are commonly added. For oral administration in capsule form, useful diluents include lactose and dried
20 corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents may be added. For intramuscular, intraperitoneal, subcutaneous and intravenous use, sterile solutions of the active ingredient are usually prepared, and the
25 pH of the solutions should be suitably adjusted and buffered. For intravenous use, the total concentration of solutes should be controlled in order to render the preparation isotonic.

The compounds of the instant invention may also be co-administered with other well known therapeutic agents that are
30 selected for their particular usefulness against the condition that is being treated. For example, the instant compounds may be useful in combination with known anti-cancer and cytotoxic agents. Similarly, the instant compounds may be useful in combination with agents that are effective in the treatment and prevention of NF-1, retinosis, polycystic

- 77 -

kidney disease, infections of hepatitis delta and related viruses and fungal infections.

If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent(s) within its approved dosage range. Compounds of the instant invention may alternatively be used sequentially with known pharmaceutically acceptable agent(s) when a combination formulation is inappropriate.

The present invention also encompasses a pharmaceutical composition useful in the treatment of cancer, comprising the administration of a therapeutically effective amount of the compounds of this invention, with or without pharmaceutically acceptable carriers or diluents. Suitable compositions of this invention include aqueous solutions comprising compounds of this invention and pharmacologically acceptable carriers, e.g., saline, at a pH level, e.g., 7.4. The solutions may be introduced into a patient's blood-stream by local bolus injection.

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specific amounts, as well as any product which results, directly or indirectly, from combination of the specific ingredients in the specified amounts.

When a compound according to this invention is administered into a human subject, the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms.

In one exemplary application, a suitable amount of compound is administered to a mammal undergoing treatment for cancer. Administration occurs in an amount between about 0.1 mg/kg of body weight to about 60 mg/kg of body weight per day, preferably of between 0.5 mg/kg of body weight to about 40 mg/kg of body weight per day.

The compounds of the instant invention are also useful as a component in an assay to rapidly determine the presence and

- 78 -

quantity of farnesyl-protein transferase (FPTase) in a composition. Thus the composition to be tested may be divided and the two portions contacted with mixtures which comprise a known substrate of FPTase (for example a tetrapeptide having a cysteine at the amine terminus) and farnesyl pyrophosphate and, in one of the mixtures, a compound of the instant invention. After the assay mixtures are incubated for an sufficient period of time, well known in the art, to allow the FPTase to farnesylate the substrate, the chemical content of the assay mixtures may be determined by well known immunological, radiochemical or chromatographic techniques. Because the compounds of the instant invention are selective inhibitors of FPTase, absence or quantitative reduction of the amount of substrate in the assay mixture without the compound of the instant invention relative to the presence of the unchanged substrate in the assay containing the instant compound is indicative of the presence of FPTase in the composition to be tested.

It would be readily apparent to one of ordinary skill in the art that such an assay as described above would be useful in identifying tissue samples which contain farnesyl-protein transferase and quantitating the enzyme. Thus, potent inhibitor compounds of the instant invention may be used in an active site titration assay to determine the quantity of enzyme in the sample. A series of samples composed of aliquots of a tissue extract containing an unknown amount of farnesyl-protein transferase, an excess amount of a known substrate of FPTase (for example a tetrapeptide having a cysteine at the amine terminus) and farnesyl pyrophosphate are incubated for an appropriate period of time in the presence of varying concentrations of a compound of the instant invention. The concentration of a sufficiently potent inhibitor (i.e., one that has a K_i substantially smaller than the concentration of enzyme in the assay vessel) required to inhibit the enzymatic activity of the sample by 50% is approximately equal to half of the concentration of the enzyme in that particular sample.

- 79 -

EXAMPLES

Examples provided are intended to assist in a further understanding of the invention. Particular materials employed, species
5 and conditions are intended to be further illustrative of the invention and not limitative of the reasonable scope thereof.

EXAMPLE 1

10 1-(2-[Thien-2-yl]pyrid-5-ylmethyl)-5-(4-cyanobenzyl)imidazole.

Step A: 2-Trifluoromethanesulfonyloxy-5-pyridinecarboxylic acid

To a solution of 2-hydroxy 5-pyridinecarboxylic acid (185 mg, 1.33 mmol) and diisopropylethylamine (0.464 mL, 2.66
15 mmol) in dichloromethane (7 mL) at -78°C is added trifluoromethane-sulfonic anhydride (0.224 mL, 1.33 mmol) and the mixture stirred at -78°C for 1 hour and then at ambient temperature for 1 hour. The reaction is diluted with water and extracted with CH₂Cl₂, and the organic extract is dried, (MgSO₄) and the solvent is evaporated in
20 vacuo. The residue is purified by chromatography to afford the title compound.

Step B: 2-(Thien-2-yl)-5-pyridinecarboxylic acid

A mixture of 2-trifluoromethanesulfonyloxy-5-pyridine-carboxylic acid (0.442 g, 1.72 mmol), 2-thienylboronic acid (1.56 g, 12.79 mmol), barium hydroxide (0.813 mg, 2.58 mmol), DME (8 mL) and water (1.5 mL) is purged with dry argon. Tetrakis(triphenyl-phosphine) palladium(0) (99.0 mg, 0.086 mmol) is added, and the resultant solution is stirred at 80 °C for 4 hours. The solvents are
25 evaporated in vacuo, and the residue is partitioned between EtOAc and water. The aqueous extract is separated, and extracted with EtOAc. The organic extracts are combined, washed with sat. aq. NaHCO₃ and 5% aq. Na₂S₂O₃, dried, (Na₂SO₄) and the solvent is evaporated in

- 80 -

vacuo. The residue is purified by chromatography to afford the title compound.

Step C: 2-(Thien-2-yl)-5-hydroxymethylpyridine

5 To a solution of 2-(thien-2-yl)-5-pyridinecarboxylic acid (0.333 g, 1.60 mmol) in THF (5 mL) at 0°C is added 1.0 M lithium aluminum hydride in diethyl ether (1.60 mL, 1.60 mmol) over 10 minutes. The reaction is allowed to stir at ambient temperature for 3 hours, cooled to 0°C, and water (0.10 mL), 4 N aq. NaOH (0.10 mL),
10 and water (0.30 mL) are added sequentially. The reaction is filtered through a pad of Celite and the filtrate is evaporated in vacuo. The residue is purified by chromatography to afford the title compound.

Step D: 1-(2-(Thien-2-yl) pyrid-5-ylmethyl)-5-(4-cyanobenzyl)imidazole

15 To a solution of 2-(thien-2-yl)-5-hydroxymethylpyridine (255 mg, 1.33 mmol) and diisopropylethylamine (0.464 mL, 2.66 mmol) in dichloromethane (7 mL) at -78°C is added trifluoromethane-sulfonic anhydride (0.224 mL, 1.33 mmol) and the mixture stirred at
20 -78°C for 1 hour. To this mixture is added a solution of 1-trityl-4-(4-cyanobenzyl)-imidazole (566mg , 1.33 mmol) in dichloromethane (5 mL). The mixture is allowed to warm to ambient temperature and stirred for 2 hours. The solvent is evaporated in vacuo. The residue is dissolved in methanol (50 mL). heated at reflux for 1 hour, and the
25 solvent is evaporated in vacuo. The residue is partitioned between dichloromethane and sat. aq. NaHCO₃ solution. The organic layer is dried, (Na₂SO₄) and the solvent evaporated in vacuo. The residue is chromatographed to afford the title compound.

30

- 81 -

EXAMPLE 2

N-{1-(4-Cyanobenzyl)-1H-imidazol-5-yl)methyl}-5-(thien-2-yl)-2-amino-pyrimidine

5 Step A: 5-(Thien-2-yl)-2-aminopyrimidine

A mixture of 2-amino-5-bromopyrimidine (0.299 g, 1.72 mmol), 2-thienylboronic acid (1.56 g, 12.79 mmol), barium hydroxide (0.813 mg, 2.58 mmol), DME (8 mL) and water (1.5 mL) is purged
10 with dry argon. Tetrakis(triphenyl-phosphine) palladium(0) (99.0 mg, 0.086 mmol) is added, and the resultant solution is stirred at 80°C for 4 hours. The solvents are evaporated in vacuo, and the residue is partitioned between EtOAc and water. The aqueous extract is separated, and extracted with EtOAc. The organic extracts are
15 combined, washed with sat. aq. NaHCO₃ and 5% aq. Na₂S₂O₃, dried, (Na₂SO₄) and the solvent is evaporated in vacuo. The residue is purified by chromatography to afford the title compound.

20 Step B: 1-Triphenylmethyl-4-(hydroxymethyl)imidazol

To a solution of 4-(hydroxymethyl)imidazole hydrochloride (35.0 g, 260 mmol) in dry DMF (250 mL) at room temperature was added triethylamine (90.6 mL, 650 mmol). A white solid precipitated from the solution. Chlorotriphenylmethane (76.1 g, 273 mmol) in DMF (500 mL) was added dropwise. The reaction
25 mixture was stirred for 20 hours, poured over ice, filtered, and washed with ice water. The resulting product was slurried with cold dioxane, filtered, and dried in vacuo to provide the titled product as a white solid which was sufficiently pure for use in the next step.

30 Step C: 1-Triphenylmethyl-4-(acetoxymethyl)imidazole

The alcohol from Step B (260 mmol, prepared above) was suspended in pyridine (500 mL). Acetic anhydride (74 mL, 780 mmol)
- was added dropwise, and the reaction was stirred for 48 hours during which it became homogeneous. The solution was poured into EtOAc,
35 washed sequentially with water, 5% aq. HCl solution, sat. aq. NaHCO₃,

solution, and brine. The organic extracts were dried, (Na_2SO_4), and concentrated in vacuo to provide the product as a white powder, which was sufficiently pure for use in the next reaction.

5 Step D: 1-(4-Cyanobenzyl)-5-(acetoxymethyl)imidazole
hydrobromide

A solution of the product from Step C (85.8 g, 225 mmol) and 4-cyano benzyl bromide (50.1 g, 232 mmol) in EtOAc (500 mL) was stirred at 60°C for 20 hours, during which a pale yellow precipitate formed. The reaction was cooled to room temperature and filtered to provide the solid imidazolium bromide salt. The filtrate was concentrated in vacuo to a volume (200 mL), heated at 60°C for 2 hours, cooled to room temperature, and filtered. The filtrate was concentrated in vacuo to a volume (100 mL), heated at 60°C for 2 hours, cooled to room temperature, and concentrated in vacuo to provide a pale yellow solid. All of the solid material was combined, dissolved in methanol (500 mL), and warmed to 60°C. After 2 hours, the solution was concentrated in vacuo to provide a white solid which was triturated with hexane to remove soluble by products. Removal of residual solvents in vacuo provided the titled product as a white solid which was used in the next step without further purification.

Step E: 1-(4-Cyanobenzyl)-5-(hydroxymethyl)imidazole

To a solution of the acetate from Step D (50.4 g, 150 mmol) in 3:1 THF/water (1.5 L) at 0 °C was added lithium hydroxide monohydrate (18.9 g, 450 mmol). After 1 hour, the reaction was concentrated in vacuo, diluted with EtOAc (3 L), and washed with water, sat. aq. NaHCO_3 and brine. The solution was then dried (Na_2SO_4), filtered, and concentrated in vacuo to provide the crude product as a pale yellow fluffy solid which was sufficiently pure for use in the next step without further purification.

- 83 -

Step F: 1-(4-Cyanobenzyl)-5-(chloromethyl)imidazole

A solution of 1-(4-cyanobenzyl)-5-(hydroxymethyl)imidazole (1.00g, 4.70 mmol), in thionyl chloride (5 mL), was stirred at 70°C for 16 hours. The solvent was evaporated in vacuo and the resulting solid suspended in CH₂Cl₂, collected by filtration and dried in vacuo. The material was sufficiently pure for use in the next step without further purification.

¹H NMR (CD₃OD 400MHz) δ 9.06 (1H, s), 7.83(2H, d, J=8.0Hz), 7.77(1H, s), 7.55(2H, d, J=8.0Hz), 5.67(2H, s) and 4.78(2H, s) ppm.

Step G: N-{1-(4-Cyanobenzyl)-1H-imidazol-5-yl)methyl}-5-(thien-2-yl)-2-aminopyrimidine

To a solution of the chloride from step F (500mg, 1.65 mmol) in DMF (10 mL) at 0°C is added sequentially, the amine from step A (292mg, 1.65 mmol) and sodium hydride (145mg, 60% dispersion in mineral oil, 3.62 mmol). Stirring is continued at 0°C for 1 hour and then at room temperature for 16 hours. The reaction is quenched with water (50 mL), and extracted with CH₂Cl₂. The organic extracts are dried, (MgSO₄), and the solvent is evaporated in vacuo. The residue is purified by chromatography to afford the title compound

EXAMPLE 3In vitro inhibition of ras farnesyl transferase

Assays of farnesyl-protein transferase. Partially purified bovine FPTase and Ras peptides (Ras-CVLS, Ras-CVIM and Ras-CAIL) were prepared as described by Schaber *et al.*, *J. Biol. Chem.* 265:14701-14704 (1990), Pompliano, *et al.*, *Biochemistry* 31:3800 (1992) and Gibbs *et al.*, *PNAS* U.S.A. 86:6630-6634 (1989), respectively. Bovine FPTase was assayed in a volume of 100 µl containing 100 mM N-(2-hydroxy ethyl) piperazine-N'-(2-ethane sulfonic acid) (HEPES), pH 7.4, 5 mM MgCl₂, 5 mM dithiothreitol (DTT), 100 mM [³H]-farnesyl diphosphate ([³H]-FPP; 740 CBq/mmol, New England Nuclear), 650 nM Ras-CVLS and 10 µg/ml FPTase at 31°C for 60 min. Reactions

- 84 -

were initiated with FPTase and stopped with 1 ml of 1.0 M HCL in ethanol. Precipitates were collected onto filter-mats using a TomTec Mach II cell harvester, washed with 100% ethanol, dried and counted in an LKB β -plate counter. The assay was linear with respect to both
5 substrates, FPTase levels and time; less than 10% of the [^3H]-FPP was utilized during the reaction period. Purified compounds were dissolved in 100% dimethyl sulfoxide (DMSO) and were diluted 20-fold into the assay. Percentage inhibition is measured by the amount of
10 incorporation of radioactivity in the presence of the test compound when compared to the amount of incorporation in the absence of the test compound.

Human FPTase was prepared as described by Omer et al., Biochemistry 32:5167-5176 (1993). Human FPTase activity was assayed as described above with the exception that 0.1% (w/v)
15 polyethylene glycol 20,000, 10 μM ZnCl_2 and 100 nM Ras-CVIM were added to the reaction mixture. Reactions were performed for 30 min., stopped with 100 μl of 30% (v/v) trichloroacetic acid (TCA) in ethanol and processed as described above for the bovine enzyme.

The compounds of the instant invention are tested for
20 inhibitory activity against human FPTase by the assay described above.

EXAMPLE 4

In vivo ras farnesylation assay

25 The cell line used in this assay is a v-ras line derived from either Rat1 or NIH3T3 cells, which expressed viral Ha-ras p21. The assay is performed essentially as described in DeClue, J.E. et al., Cancer Research 51:712-717, (1991). Cells in 10 cm dishes at 50-75% confluency are treated with the test compound (final concentration of
30 solvent, methanol or dimethyl sulfoxide, is 0.1%). After 4 hours at 37°C, the cells are labelled in 3 ml methionine-free DMEM supplemented with 10% regular DMEM, 2% fetal bovine serum and 400 mCi[^{35}S]methionine (1000 Ci/mmol). After an additional 20 hours, the
cells are lysed in 1 ml lysis buffer (1% NP40/20 mM HEPES, pH 7.5/5

- 85 -

mM MgCl₂/1mM DTT/10 mg/ml aprotinen/2 mg/ml leupeptin/2 mg/ml antipain/0.5 mM PMSF) and the lysates cleared by centrifugation at 100,000 x g for 45 min. Aliquots of lysates containing equal numbers of acid-precipitable counts are brought to 1 ml with IP buffer (lysis
5 buffer lacking DTT) and immunoprecipitated with the ras-specific monoclonal antibody Y13-259 (Furth, M.E. et al., J. Viro. 43:294-304, (1982)). Following a 2 hour antibody incubation at 4°C, 200 ml of a 25% suspension of protein A-Sepharose coated with rabbit anti rat IgG is added for 45 min. The immunoprecipitates are washed four times
10 with IP buffer (20 nM HEPES, pH 7.5/1 mM EDTA/1% Triton X-100/0.5% deoxycholate/0.1%/SDS/0.1 M NaCl) boiled in SDS-PAGE sample buffer and loaded on 13% acrylamide gels. When the dye front reached the bottom, the gel is fixed, soaked in Enlightening, dried and autoradiographed. The intensities of the bands corresponding to
15 farnesylated and nonfarnesylated ras proteins are compared to determine the percent inhibition of farnesyl transfer to protein.

EXAMPLE 5

20 *In vivo* growth inhibition assay

To determine the biological consequences of FPTase inhibition, the effect of the compounds of the instant invention on the anchorage-independent growth of Rat1 cells transformed with either a *v-ras*, *v-raf*, or *v-mos* oncogene is tested. Cells transformed by v-Raf
25 and v-Mos maybe included in the analysis to evaluate the specificity of instant compounds for Ras-induced cell transformation.

Rat 1 cells transformed with either *v-ras*, *v-raf*, or *v-mos* are seeded at a density of 1×10^4 cells per plate (35 mm in diameter) in a 0.3% top agarose layer in medium A (Dulbecco's modified Eagle's
30 medium supplemented with 10% fetal bovine serum) over a bottom agarose layer (0.6%). Both layers contain 0.1% methanol or an appropriate concentration of the instant compound (dissolved in methanol at 1000 times the final concentration used in the assay).


- 86 -

The cells are fed twice weekly with 0.5 ml of medium A containing 0.1% methanol or the concentration of the instant compound. Photomicrographs are taken 16 days after the cultures are seeded and comparisons are made.

- 87 -

WHAT IS CLAIMED IS:

1. A compound which inhibits farnesyl-protein transferase of the formula A:



5

A

wherein:

a is N or C;

10 from 0-4 of b, c, d and e are independently N, NH, O and S, and the remaining b, c, d and e atoms are independently CH, provided that if a is C, then at least one of b, c, d or e is independently N, NH, O or S;

15 from 1-2 of f(s) are independently N, and the remaining f's are independently CH;

R^1 and R^2 are independently selected from:

- a) hydrogen,
- b) aryl, heterocycle, C_3 - C_{10} cycloalkyl, C_2 - C_6 alkenyl,
- 20 C_2 - C_6 alkynyl, $R^{10}O$ -, $R^{11}S(O)_m$ -, $R^{10}C(O)NR^{10}$ -,
 $R^{11}C(O)O$ -, $(R^{10})_2NC(O)$ -, $R^{10}_2N-C(NR^{10})$ -, CN, NO_2 ,
 $R^{10}C(O)$ -, N_3 , $-N(R^{10})_2$, or $R^{11}OC(O)NR^{10}$ -,

- 88 -

- 5 c) unsubstituted or substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹⁰O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;

R³, R⁴ and R⁵ are independently selected from:

- 10 a) hydrogen,
 b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹¹C(O)O-,
 15 R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
 c) unsubstituted C₁-C₆ alkyl,
 d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or
 20 substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;
 25 provided that when R³, R⁴ or R⁵ is unsubstituted or substituted heterocycle, attachment of R³, R⁴ or R⁵ to the six-membered heteroaryl ring is through a substitutable heterocycle ring carbon;


30 R^{6a}, R^{6b}, R^{6c} and R^{6d} are independently selected from:

- a) hydrogen,
 b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-,

- 89 -

- $R^{11}S(O)_m-$, $R^{10}C(O)NR^{10}-$, $(R^{10})_2NC(O)-$, $R^{11}C(O)O-$,
 $R^{10}_2N-C(NR^{10})-$, CN, NO₂, $R^{10}C(O)-$, N₃, $-N(R^{10})_2$,
 or $R^{11}OC(O)NR^{10}-$,
 5 c) unsubstituted C₁-C₆ alkyl,
 d) substituted C₁-C₆ alkyl wherein the substituent on the
 substituted C₁-C₆ alkyl is selected from unsubstituted or
 substituted aryl, unsubstituted or substituted heterocyclic,
 C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,
 $R^{12}O-$, $R^{11}S(O)_m-$, $R^{10}C(O)NR^{10}-$, $(R^{10})_2NC(O)-$,
 10 $R^{10}_2N-C(NR^{10})-$, CN, $R^{10}C(O)-$, N₃, $-N(R^{10})_2$, and
 $R^{11}OC(O)-NR^{10}-$;

R^7 is selected from: H; C₁-4 alkyl, C₃-6 cycloalkyl, heterocycle, aryl,
 aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or
 15 substituted with:

- a) C₁-4 alkoxy,
 b) aryl or heterocycle,
 c) halogen,
 d) HO,
 e) ,
 20 f) $-SO_2R^{11}$,
 g) $N(R^{10})_2$ or
 h) C₁-4 perfluoroalkyl;

R^8 is independently selected from:

- 25 a) hydrogen,
 b) aryl, substituted aryl, heterocycle, C₃-C₁₀ cycloalkyl,
 C₂-C₆ alkenyl, C₂-C₆ alkynyl, perfluoroalkyl, F, Cl, Br,
 $R^{10}O-$, $R^{11}S(O)_m-$, $R^{10}C(O)NR^{10}-$, $(R^{10})_2NC(O)-$,
 $R^{10}_2N-C(NR^{10})-$, CN, NO₂, $R^{10}C(O)-$, N₃, $-N(R^{10})_2$,
 30 or $R^{11}OC(O)NR^{10}-$, and

- 90 -

- 5 c) C₁-C₆ alkyl unsubstituted or substituted by aryl, cyanophenyl, heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, perfluoroalkyl, F, Cl, Br, R¹⁰O-, R¹¹S(O)_m-, R¹⁰C(O)NH-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹⁰OC(O)NH-;
- provided that when R⁸ is heterocycle, attachment of R⁸ to V is through a substitutable ring carbon;

10 R⁹ is independently selected from:

- a) hydrogen,
- b) C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, Br, R¹¹O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-, and
- 15 c) C₁-C₆ alkyl unsubstituted or substituted by perfluoroalkyl, F, Cl, Br, R¹⁰O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-;

20

R¹⁰ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl, 2,2,2-trifluoroethyl and aryl;

R¹¹ is independently selected from C₁-C₆ alkyl and aryl;

25

R¹² is independently selected from hydrogen, C₁-C₆ alkyl, C₁-C₆ aralkyl, C₁-C₆ substituted aralkyl, C₁-C₆ heteroaralkyl, C₁-C₆ substituted heteroaralkyl, aryl, substituted aryl, heteroaryl, substituted heteraryl, C₁-C₆ perfluoroalkyl, 2-aminoethyl and 2,2,2-trifluoroethyl;

30

A¹ and A² are independently selected from: a bond, -CH=CH-, -C≡C-, -C(O)-, -C(O)NR¹⁰-, -NR¹⁰C(O)-, O, -N(R¹⁰)-, -S(O)₂N(R¹⁰)-, -N(R¹⁰)S(O)₂-, or S(O)_m;

- 91 -

V is selected from:

- a) hydrogen,
- b) heterocycle,
- 5 c) aryl,
- d) C₁-C₂₀ alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and
- e) C₂-C₂₀ alkenyl,

provided that V is not hydrogen if A¹ is S(O)_m and V is not hydrogen
 10 if A¹ is a bond, n is 0 and A² is S(O)_m;
 provided that when V is heterocycle, attachment of V to R⁸ and to A¹ is through a substitutable ring carbon;

W is a heterocycle;

15

X is a bond, -CH=CH-, O, -C(=O)-, -C(O)NR⁷-, -NR⁷C(O)-, -C(O)O-,
 -OC(O)-, -C(O)NR⁷C(O)-, -NR⁷-, -S(O)₂N(R¹⁰)-, -N(R¹⁰)S(O)₂- or
 -S(=O)_m-;

20 m is 0, 1 or 2;

n is independently 0, 1, 2, 3 or 4;

p is independently 0, 1, 2, 3 or 4;

q is 0, 1, 2 or 3;


r is 0 to 5, provided that r is 0 when V is hydrogen; and

25 t is 0 or 1;

or a pharmaceutically acceptable salt thereof.

2. The compound according to Claim 1 of the formula A:

- 92 -



wherein:

a is N or C:

5

from 0-4 of b, c, d and e are independently N, NH, O and S, and the remaining b, c, d and e atoms are independently CH, provided that if a is C, then at least one of b, c, d or e is independently N, NH, O or S;

10 from 1-2 of f(s) are independently N, and the remaining f's are
independently CH;

R¹ is independently selected from: hydrogen, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂, F or C₁-C₆ alkyl;

15

R^2 is independently selected from:

a) hydrogen,

b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂, F or C₂-C₆ alkenyl,

20 c) unsubstituted or substituted C₁-C₆ alkyl wherein the
 substituent on the substituted C₁-C₆ alkyl is selected from
 unsubstituted or substituted aryl, heterocycle, C₃-C₁₀
 cycloalkyl, C₂-C₆ alkenyl, R¹⁰O- and -N(R¹⁰)₂;

25 R^3, R^4 and R^5 are independently selected from:


- 93 -

- 5
- a) hydrogen,
 - b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
 - c) unsubstituted C₁-C₆ alkyl;
 - d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;
- 10
- 15
- provided that when R³, R⁴ or R⁵ is unsubstituted or substituted heterocycle, attachment of R³, R⁴ or R⁵ to the six-membered heteroaryl ring is through a substitutable heterocycle ring carbon;
- 20
- R^{6a}, R^{6b}, R^{6c} and R^{6d} are independently selected from:
- a) hydrogen,
 - b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
 - c) unsubstituted C₁-C₆ alkyl;
 - d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic,
- 25
- 30

- 94 -

C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-,
 R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-,
 CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;

5 R⁷ is selected from: H; C₁-4 alkyl, C₃-6 cycloalkyl, heterocycle, aryl,
 aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or
 substituted with:

- 10 a) C₁-4 alkoxy,
 b) aryl or heterocycle,
 c) halogen,
 d) HO,
 e) ,
 f) —SO₂R¹¹,
 g) N(R¹⁰)₂ or
 h) C₁-4 perfluoroalkyl;

15 R⁸ is independently selected from:

- a) hydrogen,
 b) aryl, substituted aryl, heterocycle, C₁-C₆ alkyl, C₂-C₆
 20 alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl,
 R¹⁰O-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-,
 R¹⁰C(O)-, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-, and
 c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R¹⁰O-,
 R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-,
 -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-;
 25 provided that when R⁸ is heterocycle, attachment of R⁸ to V is
 through a substitutable ring carbon;

R⁹ is selected from:

- 30 a) hydrogen,
 b) C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F,
 Cl, R¹¹O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-,

- 95 -

CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or
R¹¹OC(O)NR¹⁰-, and

- 5 c) C₁-C₆ alkyl unsubstituted or substituted by C₁-C₆
perfluoroalkyl, F, Cl, R¹⁰O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-,
(R¹⁰)₂NC(O)-, CN, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-,
-N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-;

R¹⁰ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl,
2,2,2-trifluoroethyl and aryl;

10

R¹¹ is independently selected from C₁-C₆ alkyl and aryl;

R¹² is independently selected from hydrogen, C₁-C₆ alkyl, C₁-C₆
aralkyl, C₁-C₆ substituted aralkyl, C₁-C₆ heteroaralkyl,
15 C₁-C₆ substituted heteroaralkyl, aryl, substituted aryl,
heteroaryl, substituted heteraryl, C₁-C₆ perfluoroalkyl,
2-aminoethyl and 2,2,2-trifluoroethyl;

20 A¹ and A² are independently selected from: a bond, -CH=CH-, -C≡C-,
-C(O)-, -C(O)NR¹⁰-, O, -N(R¹⁰)-, or S(O)_m;

V is selected from:

- 25 a) hydrogen,
b) heterocycle selected from pyrrolidinyl, imidazolyl,
imidazolinyl, pyridinyl, thiazolyl, oxazolyl, indolyl,
quinolinyl, isoquinolinyl, triazolyl and thienyl,
c) aryl,
d) C₁-C₂₀ alkyl wherein from 0 to 4 carbon atoms are
replaced with a heteroatom selected from O, S, and N, and
30 e) C₂-C₂₀ alkenyl, and

provided that V is not hydrogen if A¹ is S(O)_m and V is not hydrogen
if A¹ is a bond, n is 0 and A² is S(O)_m;

provided that when V is heterocycle, attachment of V to R⁸ and to A¹ is
through a substitutable ring carbon;

- 96 -

W is a heterocycle selected from pyrrolidinyl, imidazolyl, imidazoliny, pyridinyl, thiazolyl, oxazolyl, indolyl, quinolinyl, triazolyl or isoquinolinyl;

5

X is a bond, O, -C(=O)-, -CH=CH-, -C(O)NR⁷-, -NR⁷C(O)-, -NR⁷-, -S(O)₂N(R¹⁰)-, -N(R¹⁰)S(O)₂- or -S(=O)_m-;

m is 0, 1 or 2;

10 n is independently 0, 1, 2, 3 or 4;

p is independently 0, 1, 2, 3 or 4;

q is 0, 1, 2 or 3;


r is 0 to 5, provided that r is 0 when V is hydrogen; and

t is 0 or 1;

15

or a pharmaceutically acceptable salt thereof.

3. The compound according to Claim 1 of the formula B:



20 wherein:

a is N or C;

from 0-4 of b, c, d and e are independently N, NH, O and S, and the remaining b, c, d and e atoms are independently CH, provided that if a is C, then at least one of b, c, d or e is independently N, NH, O or S;

25

- 97 -

from 1-2 of f(s) are independently N, and the remaining f's are independently CH;

- 5 R¹ is independently selected from: hydrogen, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂, F or C₁-C₆ alkyl;

R² is independently selected from:

- 10 a) hydrogen,
b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂, F or C₂-C₆ alkenyl,
c) unsubstituted or substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, R¹⁰O- and -N(R¹⁰)₂;
- 15

R³ and R⁴ are independently selected from:

- 20 a) hydrogen,
b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
25 c) unsubstituted C₁-C₆ alkyl,
d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,
30 R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;

provided that when R³ or R⁴ is unsubstituted or substituted heterocycle, attachment of R³ or R⁴ to the six-membered

- 98 -

heteroaryl ring is through a substitutable heterocycle ring carbon;

R^{6a}, R^{6b}, R^{6c} and R^{6d} are independently selected from:

- 5 a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
- 10 c) unsubstituted C₁-C₆ alkyl,
- d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;
- 15
- 20

R⁸ is independently selected from:

- a) hydrogen,
- b) aryl, substituted aryl, heterocycle, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-, and
- 25 c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-;
- 30

provided that when R⁸ is heterocycle, attachment of R⁸ to V is through a substitutable ring carbon;

R^{9a} and R^{9b} are independently hydrogen, C₁-C₆ alkyl, trifluoromethyl and halogen;

- 99 -

R¹⁰ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl, 2,2,2-trifluoroethyl and aryl;

5 R¹¹ is independently selected from C₁-C₆ alkyl and aryl;

R¹² is independently selected from hydrogen, C₁-C₆ alkyl, C₁-C₆ aralkyl, C₁-C₆ substituted aralkyl, C₁-C₆ heteroaralkyl, C₁-C₆ substituted heteroaralkyl, aryl, substituted aryl, heteroaryl, substituted heteraryl, C₁-C₆ perfluoroalkyl, 2-aminoethyl and 2,2,2-trifluoroethyl;

A¹ and A² are independently selected from: a bond, -CH=CH-, -C≡C-, -C(O)-, -C(O)NR¹⁰-, O, -N(R¹⁰)-, or S(O)_m;

15

V is selected from:

- a) hydrogen,
- b) heterocycle selected from pyrrolidinyl, imidazolyl, imidazoliny, pyridinyl, thiazolyl, oxazolyl, indolyl, quinolinyl, isoquinolinyl, triazolyl and thienyl,
- c) aryl,
- d) C₁-C₂₀ alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and
- e) C₂-C₂₀ alkenyl, and

25 provided that V is not hydrogen if A¹ is S(O)_m and V is not hydrogen if A¹ is a bond, n is 0 and A² is S(O)_m;
provided that when V is heterocycle, attachment of V to R⁸ and to A¹ is through a substitutable ring carbon;

30 X is a bond, -CH=CH-, -C(O)NR¹⁰-, -NR¹⁰C(O)-, -NR¹⁰-, O or -C(=O)-;

m is 0, 1 or 2;

n is independently 0, 1, 2, 3 or 4;


- 100 -

p is 0, 1, 2, 3 or 4; and
 r is 0 to 5, provided that r is 0 when V is hydrogen;

or a pharmaceutically acceptable salt thereof.

5

4. The compound according to Claim 1 of the formula C:



wherein:

10 a is N or C;

from 0-4 of b, c, d and e are independently N, NH, O and S, and the remaining b, c, d and e atoms are independently CH, provided that if a is C, then at least one of b, c, d or e is independently N, NH, O or S;

15

from 1-2 of f(s) are independently N, and the remaining f's are independently CH;

R¹ is independently selected from: hydrogen, C₃-C₁₀ cycloalkyl,

20 R¹⁰O-, -N(R¹⁰)₂, F or C₁-C₆ alkyl;

R² is independently selected from:

a) hydrogen,

b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂, F or C₂-C₆ alkenyl,

25

- 101 -

- c) unsubstituted or substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, R¹⁰O- and -N(R¹⁰)₂;

5

R³ and R⁴ are independently selected from:

- a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, CN(R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
- c) unsubstituted C₁-C₆ alkyl,
- d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;

20

25

provided that when R³ or R⁴ is unsubstituted or substituted heterocycle, attachment of R³ or R⁴ to the six-membered heteroaryl ring is through a substitutable heterocycle ring carbon;

R^{6a}, R^{6b}, R^{6c} and R^{6d} are independently selected from:

- a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, CN(R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,

30

- 102 -

- c) unsubstituted C₁-C₆ alkyl,
 d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl,
 5 C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-, R¹¹S(O)_m-,
 R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN,
 R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;

R⁸ is independently selected from:

- 10 a) hydrogen,
 b) aryl, substituted aryl, heterocycle, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-, and
 15 c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-;

provided that when R⁸ is heterocycle, attachment of R⁸ to V is through a substitutable ring carbon;

20 R^{9a} and R^{9b} are independently hydrogen, C₁-C₆ alkyl, trifluoromethyl and halogen;

25 R¹⁰ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl, 2,2,2-trifluoroethyl and aryl;

R¹¹ is independently selected from C₁-C₆ alkyl and aryl;

30 R¹² is independently selected from hydrogen, C₁-C₆ alkyl, C₁-C₆ aralkyl, C₁-C₆ substituted aralkyl, C₁-C₆ heteroaralkyl, C₁-C₆ substituted heteroaralkyl, aryl, substituted aryl, heteroaryl, substituted heteraryl, C₁-C₆ perfluoroalkyl, 2-aminoethyl and 2,2,2-trifluoroethyl;

- 103 -

A¹ and A² are independently selected from: a bond, -CH=CH-, -C≡C-, -C(O)-, -C(O)NR¹⁰-, O, -N(R¹⁰)-, or S(O)_m;

V is selected from:

- 5 a) hydrogen,
- b) heterocycle selected from pyrrolidinyl, imidazolyl, imidazolinyl, pyridinyl, thiazolyl, oxazolyl, indolyl, quinolinyl, isoquinolinyl, triazolyl and thienyl,
- c) aryl,
- 10 d) C₁-C₂₀ alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and
- e) C₂-C₂₀ alkenyl, and

provided that V is not hydrogen if A¹ is S(O)_m and V is not hydrogen if A¹ is a bond, n is 0 and A² is S(O)_m;

- 15 provided that when V is heterocycle, attachment of V to R⁸ and to A¹ is through a substitutable ring carbon;

X is a bond, -CH=CH-, -C(O)NR¹⁰-, -NR¹⁰C(O)-, -NR¹⁰-, O or -C(=O)-;

20

m is 0, 1 or 2;

n is independently 0, 1, 2, 3 or 4;


p is 0, 1, 2, 3 or 4, provided that p is not 0 if X is a bond or O; and

- 25 r is 0 to 5, provided that r is 0 when V is hydrogen;

or a pharmaceutically acceptable salt thereof.

5. The compound according to Claim 3 of the formula D:

- 104 -



wherein:

a is N or C;

5

from 0-4 of b, c, d and e are independently N, NH, O and S, and the remaining b, c, d and e atoms are independently CH, provided that if a is C, then at least one of b, c, d or e is independently N, NH, O or S;

10 from 1-2 of f(s) are independently N, and the remaining f's are independently CH;

R¹ is independently selected from: hydrogen, C₃-C₁₀ cycloalkyl or C₁-C₆ alkyl;

15

R² is independently selected from:

- a) hydrogen,
- b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂, F or C₂-C₆ alkenyl,
- 20 c) C₁-C₆ alkyl unsubstituted or substituted by aryl, heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, R¹⁰O-, or -N(R¹⁰)₂;

R³ is selected from:

25

- a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆

- 105 -

- alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
- 5 c) unsubstituted C₁-C₆ alkyl,
- d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,
- 10 R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;
- provided that when R³ is unsubstituted or substituted heterocycle, attachment of R³ to the six-membered heteroaryl ring is
- 15 through a substitutable heterocycle ring carbon;

R⁴ is selected from H, halogen, C₁-C₆ alkyl and CF₃;

- R^{6a}, R^{6b}, R^{6c} and R^{6d} are independently selected from:
- 20 a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-,
- 25 R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
- c) unsubstituted C₁-C₆ alkyl,
- d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,
- 30 R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;

- 106 -

R⁸ is independently selected from:

- 5 a) hydrogen,
 b) aryl, substituted aryl, heterocycle, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-, and
 10 c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-;

provided that when R⁸ is heterocycle, attachment of R⁸ to V is through a substitutable ring carbon;

15 R^{9a} and R^{9b} are independently hydrogen, ethyl, cyclopropyl or methyl;

R¹⁰ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl, 2,2,2-trifluoroethyl and aryl;

20 R¹¹ is independently selected from C₁-C₆ alkyl and aryl;

25 R¹² is independently selected from hydrogen, C₁-C₆ alkyl, C₁-C₆ aralkyl, C₁-C₆ substituted aralkyl, C₁-C₆ heteroaralkyl, C₁-C₆ substituted heteroaralkyl, aryl, substituted aryl, heteroaryl, substituted heteraryl, C₁-C₆ perfluoroalkyl, 2-aminoethyl and 2,2,2-trifluoroethyl;

A¹ is selected from: a bond, -C(O)-, O, -N(R¹⁰)-, or S(O)_m;


30 X is a bond, -CH=CH-, -C(O)NR¹⁰-, -NR¹⁰C(O)-, -NR¹⁰-, O or -C(=O)-;

- n is 0 or 1;
 m is 0, 1 or 2; and
 p is 0, 1, 2, 3 or 4;

- 107 -

or a pharmaceutically acceptable salt thereof.

6. The compound according to Claim 4 of the formula E:



wherein:

a is N or C;

10 from 0-4 of b, c, d and e are independently N, NH, O and S, and the remaining b, c, d and e atoms are independently CH, provided that if a is C, then at least one of b, c, d or e is independently N, NH, O or S;

15 from 1-2 of f(s) are independently N, and the remaining f's are independently CH;

R¹ is independently selected from: hydrogen, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂, F or C₁-C₆ alkyl;

20 R² is independently selected from:

- a) hydrogen,
- b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂, F or C₂-C₆ alkenyl,

- 108 -

- c) C₁-C₆ alkyl unsubstituted or substituted by aryl, heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, R¹⁰O-, or -N(R¹⁰)₂;

5 R³ is selected from:

- a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
- c) unsubstituted C₁-C₆ alkyl,
- d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;

provided that when R³ is unsubstituted or substituted heterocycle, attachment of R³ to the six-membered heteroaryl ring is through a substitutable heterocycle ring carbon;

25 R⁴ is selected from H, halogen, C₁-C₆ alkyl and CF₃;

R^{6a}, R^{6b}, R^{6c} and R^{6d} are independently selected from:

- a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-;

- 109 -

- 5 c) unsubstituted C₁-C₆ alkyl,
 d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;

10 R⁸ is independently selected from:

- a) hydrogen,
 b) aryl, substituted aryl, heterocycle, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-, and
 15 c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-;

20 provided that when R⁸ is heterocycle, attachment of R⁸ to V is through a substitutable ring carbon;

R^{9a} and R^{9b} are independently hydrogen, ethyl, cyclopropyl or methyl;

25 R¹⁰ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl, 2,2,2-trifluoroethyl and aryl;

R¹¹ is independently selected from C₁-C₆ alkyl and aryl;

30 R¹² is independently selected from hydrogen, C₁-C₆ alkyl, C₁-C₆ aralkyl, C₁-C₆ substituted aralkyl, C₁-C₆ heteroaralkyl, C₁-C₆ substituted heteroaralkyl, aryl, substituted aryl, heteroaryl, substituted heteraryl, C₁-C₆ perfluoroalkyl, 2-aminoethyl and 2,2,2-trifluoroethyl;

- 110 -


X is a bond, -CH=CH-, -C(O)NR¹⁰-, -NR¹⁰C(O)-, -NR¹⁰-, O or -C(=O)-;

5 n is 0 or 1; provided that n is not 0 if A¹ is a bond, O, -N(R¹⁰)-, or S(O)_m;
 m is 0, 1 or 2; and
 p is 0, 1, 2, 3 or 4, provided that p is not 0 if X is a bond or O;

or a pharmaceutically acceptable salt thereof.

10

7. The compound according to Claim 5 of the formula F:



wherein:

15 a is N or C;

from 0-4 of b, c, d and e are independently N, NH, O and S, and the remaining b, c, d and e atoms are independently CH, provided that if a is C, then at least one of b, c, d or e is independently N, NH, O or S;

20

from 1-2 of f(s) are independently N, and the remaining f's are independently CH;

25 R¹ is independently selected from: hydrogen, C₃-C₁₀ cycloalkyl or C₁-C₆ alkyl;

- 111 -

R² is independently selected from:

- a) hydrogen,
- b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂ or F,
- 5 c) C₁-C₆ alkyl unsubstituted or substituted by aryl, heterocycle, C₃-C₁₀ cycloalkyl, R¹⁰O-, or -N(R¹⁰)₂;

R³ is selected from:

- a) hydrogen,
- 10 b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
- 15 c) unsubstituted C₁-C₆ alkyl,
- d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;
- 20

25 provided that when R³ is unsubstituted or substituted heterocycle, attachment of R³ to the six-membered heteroaryl ring is through a substitutable heterocycle ring carbon;

R⁴ is selected from H, halogen, CH₃ and CF₃;

30 R^{6a}, R^{6b}, R^{6c} and R^{6d} are independently selected from:

- a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆


- 112 -

- alkenyl, C2-C6 alkynyl, halogen, C1-C6 perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
- 5 c) unsubstituted C1-C6 alkyl,
 d) substituted C1-C6 alkyl wherein the substituent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl,
- 10 R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;
- R^{9a} and R^{9b} are independently hydrogen, ethyl, cyclopropyl or methyl;
- 15 R¹⁰ is independently selected from hydrogen, C1-C6 alkyl, benzyl, 2,2,2-trifluoroethyl and aryl;
- R¹¹ is independently selected from C1-C6 alkyl and aryl;
- 20 R¹² is independently selected from hydrogen, C1-C6 alkyl, C1-C6 aralkyl, C1-C6 substituted aralkyl, C1-C6 heteroaralkyl, C1-C6 substituted heteroaralkyl, aryl, substituted aryl, heteroaryl, substituted heteraryl, C1-C6 perfluoroalkyl,
- 25 2-aminoethyl and 2,2,2-trifluoroethyl;
- X is a bond, -CH=CH-, -C(O)NR¹⁰-, -NR¹⁰C(O)-, -NR¹⁰-, O or -C(=O)-;
- 30 m is 0, 1 or 2; and
 p is 0, 1, 2, 3 or 4;

or a pharmaceutically acceptable salt thereof.

- 113 -

8. The compound according to Claim 6 of the formula G:



wherein:

5 a is N or C;

from 0-4 of b, c, d and e are independently N, NH, O and S, and the remaining b, c, d and e atoms are independently CH, provided that if a is C, then at least one of b, c, d or e is independently N, NH, O or S;

10

from 1-2 of f(s) are independently N, and the remaining f's are independently CH;

R¹ is independently selected from: hydrogen, C3-C10 cycloalkyl,
15 R¹⁰O-, -N(R¹⁰)₂, F or C1-C6 alkyl;

R² is independently selected from:

- a) hydrogen,
- b) aryl or heterocycle,
- 20 c) C1-C6 alkyl unsubstituted or substituted by aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, R¹⁰O-, or -N(R¹⁰)₂;

R³ is selected from:

- 25 a) hydrogen,

- 114 -

- 5 b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
- 10 c) unsubstituted C₁-C₆ alkyl,
- d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, and R¹¹OC(O)-NR¹⁰-;
- 15 provided that when R³ is unsubstituted or substituted heterocycle, attachment of R³ to the six-membered heteroaryl ring is through a substitutable heterocycle ring carbon;

R⁴ is selected from H, halogen, CH₃ and CF₃;

20

R^{6a}, R^{6b}, R^{6c} and R^{6d} are independently selected from:

- a) hydrogen,
- 25 b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, halogen, C₁-C₆ perfluoroalkyl, R¹²O-, R¹¹S(O)_m-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂NC(O)-, R¹⁰₂N-C(NR¹⁰)-, CN, NO₂, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-,
- 30 c) unsubstituted C₁-C₆ alkyl,
- d) substituted C₁-C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,

- 115 -

$R^{12}O-$, $R^{11}S(O)_m-$, $R^{10}C(O)NR^{10}-$, $(R^{10})_2NC(O)-$,
 $R^{10}_2N-C(NR^{10})-$, CN , $R^{10}C(O)-$, N_3 , $-N(R^{10})_2$, and
 $R^{11}OC(O)-NR^{10}-$;

5

R^{9a} and R^{9b} are independently hydrogen, ethyl, cyclopropyl or methyl;

R^{10} is independently selected from hydrogen, C_1 - C_6 alkyl, benzyl,
 2,2,2-trifluoroethyl and aryl;

10

R^{11} is independently selected from C_1 - C_6 alkyl and aryl;

R^{12} is independently selected from hydrogen, C_1 - C_6 alkyl, C_1 - C_6
 aralkyl, C_1 - C_6 substituted aralkyl, C_1 - C_6 heteroaralkyl,
 15 C_1 - C_6 substituted heteroaralkyl, aryl, substituted aryl,
 heteroaryl, substituted heteraryl, C_1 - C_6 perfluoroalkyl,
 2-aminoethyl and 2,2,2-trifluoroethyl;

20

A^1 is selected from: a bond, $-C(O)-$, O , $-N(R^{10})-$, or $S(O)_m$;

m is 0, 1 or 2; and

n is 0 or 1;

or the pharmaceutically acceptable salts thereof.


25

9. A compound which inhibits farnesyl-protein
 transferase which is:

1-(2-[Thien-2-yl]pyrid-5-ylmethyl)-5-(4-cyanobenzyl)imidazole.


30

- 116 -



or

5 N-(1-(4-Cyanobenzyl)-1H-imidazol-5-yl)methyl)-5-(thien-2-yl)-2-amino-pyrimidine



10 or a pharmaceutically acceptable salt or optical isomer thereof.

10. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 1.

15

11. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 3.

20

12. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 4.

- 117 -

13. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 9.

5 14. A method for inhibiting farnesyl-protein transferase which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 10.

10 15. A method for inhibiting farnesyl-protein transferase which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 11.

15 16. A method for inhibiting farnesyl-protein transferase which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 12.

20 17. A method for inhibiting farnesyl-protein transferase which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 13.

18. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 10.

25 19. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 11.

30 20. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 12.

- 118 -

21. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 13.

5 22. A method for treating neurofibromin benign proliferative disorder which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 10.

10 23. A method for treating blindness related to retinal vascularization which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 10.

15 24. A method for treating infections from hepatitis delta and related viruses which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 10.

20 25. A method for preventing restenosis which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 10.

25 26. A method for treating polycystic kidney disease which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 10.

 27. A pharmaceutical composition made by combining the compound of Claim 1 and a pharmaceutically acceptable carrier.

30 28. A process for making a pharmaceutical composition comprising combining a compound of Claim 1 and a pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/05512

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07D 413/00; A61K 31/44

US CL : 546/272.7; 514/341

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 546/272.7; 514/341

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Please See Extra Sheet.Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
NONE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4,713,387 A (WATANABE ET AL.) 15 December 1987, see entire document.	1-13
A	US 5,428,164 A (THURKAUF ET AL.) 27 June 1995, see entire document.	1-13
A, P	US 5,587,390 A (SALIMBENI ET AL.) 24 December 1996, see entire document.	1-13
A, E	US 5,633,376 A (THURKAUF ET AL.) 27 May 1997, see entire document	1-13

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)	A	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

11 JULY 1997

Date of mailing of the international search report

04 AUG 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

FLOYD D. HIGEL

Telephone No. (703) 306-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/05512

B. FIELDS SEARCHED

Documentation other than minimum documentation that are included in the fields searched:

Chemical Abstracts
Current Abstracts of Chemistry
Index Chemicus